floxuridine has been researched along with Colorectal Cancer in 290 studies
Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to examine the efficacy of a combination treatment of sequential irinotecan and doxifluridine, an intermediate of capecitabine, evaluated by the response rate and safety in patients with metastatic colorectal cancer." | 10.23 | A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer. ( Amano, M; Fukunaga, M; Ikeda, K; Ikeda, M; Ikenaga, M; Ishida, H; Kato, T; Mishima, H; Monden, M; Murata, K; Ohnishi, T; Ota, H; Sakamoto, J; Sekimoto, M; Tominaga, S, 2008) |
| "To determine the maximum tolerated dose (MTD) and preliminary efficacy of concurrent hepatic arterial infusion (HAI) of floxuridine (FUDR) and systemic modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable hepatic metastases from colorectal cancer." | 9.19 | Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer. ( Chen, C; Chen, G; Ding, P; Gu, Y; He, Y; Li, C; Li, W; Li, Y; Lu, Z; Luo, H; Pan, Z; Wan, D; Wang, F; Wang, Z; Wu, X; Xu, R; Yuan, Y; Zhao, M, 2014) |
| "We performed a phase II study of irinotecan with 5'-deoxy-5-fluorouridine (5'-DFUR) for metastatic colorectal cancer based on UDP-glucuronosyltransferase (UGT) 1A1 polymorphism." | 9.17 | UDP-glucuronosyltransferase (UGT) 1A1*28 polymorphism-directed phase II study of irinotecan with 5'-deoxy-5-fluorouridine (5'-DFUR) for metastatic colorectal cancer. ( Araki, A; Eto, R; Hazama, S; Hinoda, Y; Kanekiyo, S; Kondo, H; Nagashima, A; Oka, M; Okayama, N; Shimizu, R; Uchiyama, T; Yamamoto, T; Yoshida, S; Yoshino, S, 2013) |
| "Twenty-nine unresectable colorectal cancer patients were stratified to either ≥70 or <60 years of age, where the disposition of capecitabine and its metabolites were compared." | 9.17 | Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030). ( Albain, KS; Blanke, CD; Coleman, D; Ely, B; Gold, PJ; Gotay, C; Lenz, HJ; Louie, SG; Raghavan, D; Shields, AF, 2013) |
| "The aim of this study was to evaluate the therapeutic efficacy and safety of hepatic arterial infusion (HAI) with irinotecan, oxaliplatin, and floxuridine as a firstline treatment in patients with unresectable liver metastases of colorectal cancer (CRC)." | 9.16 | Hepatic arterial infusion with irinotecan, oxaliplatin, and floxuridine plus systemic chemotherapy as first-line treatment of unresectable liver metastases from colorectal cancer. ( Chen, Y; Liu, Q; Luo, J; Wang, J; Wang, X; Yan, Z, 2012) |
| "To evaluate the therapeutic efficacy and safety of combination chemotherapy with oxaliplatin, irinotecan and doxifluridine through hepatic arterial infusion (HAI) in patients with unresectable liver metastases of colorectal cancer." | 9.14 | Hepatic arterial infusion with oxaliplatin, irinotecan and doxifluridine for unresectable liver metastases of colorectal cancer. ( Chen, Y; Liu, Q; Luo, J; Wang, J; Wang, X; Yan, Z, 2010) |
| "Our objectives were to determine response rate, time to progression, overall survival and tolerability of novel combination chemotherapy, consisting of irinotecan, high-dose 24-h continuous intravenous infusion of floxuridine and leucovorin in advanced previously untreated colorectal cancer." | 9.12 | A phase II study of irinotecan, high-dose 24-h continuous intravenous infusion of floxuridine and leucovorin (IFLUX) for advanced, previously untreated colorectal cancer. ( Ardalan, B; Franceschi, D; Kozyreva, O; Lima, M; Livingstone, A; Santos, E; Tsai, KT, 2007) |
| "Irinotecan (CPT-11) and doxifluridine (5'-DFUR) are active agents against colorectal cancer." | 9.11 | Sequential treatment with irinotecan and doxifluridine: optimal dosing schedule in murine models and in a phase I study for metastatic colorectal cancer. ( Fujimoto-Ouchi, K; Kato, T; Kikkawa, N; Mishima, H; Nishisho, I; Tanaka, Y; Tsujie, M; Tsujinaka, T; Yanagisawa, M, 2005) |
| "This phase II study was designed to evaluate the efficacy and toxicities of oral doxifluridine plus leucovorin as a randomized trial with those of intravenous 5-fluorouracil (5-FU) plus leucovorin in previously untreated metastatic colorectal cancer (CRC)." | 9.10 | Oral doxifluridine plus leucovorin in metastatic colorectal cancer: randomized phase II trial with intravenous 5-fluorouracil plus leucovorin. ( Ahn, JH; Kang, YK; Kim, JC; Kim, JG; Kim, TW; Kim, WK; Lee, JH; Lee, JS; Min, YJ; Yu, CS, 2003) |
| "To assess the relationship between systemic exposure to capecitabine metabolites and parameters of efficacy and safety in patients with advanced or metastatic colorectal cancer from two phase III studies." | 9.10 | Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients. ( Blesch, KS; Burger, HU; Gieschke, R; Reigner, B; Steimer, JL, 2003) |
| "This study was designed to evaluate hepatic arterial infusion of floxuridine (FUDR) in patients with resected hepatic metastases from colorectal cancer." | 9.09 | Phase II evaluation of treatment of complete resection of hepatic metastases from colorectal cancer and adjuvant hepatic arterial infusion of floxuridine: an Eastern Cooperative Oncology Group Study (PB083). ( Berlin, J; Lerner, H; Merrick, HW; Smith, TJ, 1999) |
| "This study was designed to test the activity and feasibility of an all-oral regimen of levo-leucovorin and doxifluridine (dFUR) in the treatment of advanced colorectal cancer and to establish whether the pharmacokinetics of dFUR and fluorouracil (FU) are affected by demographic and/or biologic parameters." | 9.08 | Doxifluridine and leucovorin: an oral treatment combination in advanced colorectal cancer. ( Bajetta, E; Bozzetti, F; Buzzoni, R; Cappuzzo, F; Colleoni, M; Di Bartolomeo, M; Doci, R; Guenzi, A; Somma, L; Stampino, CG, 1995) |
| "These results indicate that suramin is inactive in patients with metastatic colorectal cancer pretreated with fluoropyrimidines." | 9.08 | Suramin in patients with metastatic colorectal cancer pretreated with fluoropyrimidine-based chemotherapy. A phase II study. ( Brunetti, I; Cianci, C; Conte, PF; Danesi, R; Del Tacca, M; Falcone, A; Pfanner, E, 1995) |
| "We conducted a multicentric phase II study on advanced colorectal cancer to determine the efficacy and toxicity of oral treatment with leucovorin (LV) plus doxifluridine (5'DFUR), a novel fluoropyrimidine derivative with proven antitumor activity in different experimental models." | 9.08 | Results of leucovorin and doxifluridine oral regimen in the treatment of metastatic colorectal cancer. ( Agostino, I; Andreoli, F; Bartolini, P; Gemelli, MT; Neri, B; Pantalone, D; Pernice, ML; Scatizzi, M; Siliani, GM, 1998) |
| "This study demonstrates that a home therapy with oral doxifluridine in elderly advanced colorectal cancer patients is feasible, with a relatively low rate of toxicity, and has moderate activity, comparable to that of intravenous 5-fluorouracil." | 9.07 | Oral doxifluridine in elderly patients with metastatic colorectal cancer: a multicenter phase II study. ( Barduagni, M; Bertuccelli, M; Calabresi, F; Carrai, M; Ceribelli, A; Cianci, C; De Marco, S; Falcone, A; Pfanner, E; Ricci, S, 1994) |
| "We studied three new dose schedules of hepatic arterial infusion of floxuridine (FUDR) and leucovorin and update survival analysis of a previously reported trial using these drugs by hepatic arterial infusion for patients with hepatic metastases from colorectal carcinoma." | 9.07 | Hepatic arterial floxuridine and leucovorin for unresectable liver metastases from colorectal carcinoma. New dose schedules and survival update. ( Bertino, JR; Botet, J; Budd, AJ; Chapman, D; Cohen, A; Conti, JA; Kemeny, N; Mazumdar, M; Seiter, K; Sigurdson, ER, 1994) |
| " The purpose of this study was to compare its therapeutic effect with a standard fluorouracil (FU) regimen in patients with locally advanced or metastatic colorectal cancer." | 9.07 | Prospective randomised trial comparing fluorouracil versus doxifluridine for the treatment of advanced colorectal cancer. ( Amadori, D; Bajetta, E; Calabresi, F; Colleoni, M; Comella, G; Lorusso, V; Marangolo, M; Rosso, R; Scanni, A; Sobrero, A, 1993) |
| "This study was designed to determine if hepatic arterial therapy with floxuridine (F), mitomycin, and carmustine (BCNU) (FMB) is superior to hepatic arterial therapy with F alone in previously treated patients with hepatic metastases from colorectal cancer." | 9.07 | Randomized trial of hepatic arterial floxuridine, mitomycin, and carmustine versus floxuridine alone in previously treated patients with liver metastases from colorectal cancer. ( Botet, J; Budd, A; Cohen, A; Conti, JA; Kemeny, N; Niedzwiecki, D; Seiter, K; Sigurdson, ER; Tao, Y, 1993) |
| "Hepatic intra-arterial (HIA) infusion of floxuridine (FUDR) via an implanted pump has shown promise in the treatment of colorectal cancer metastasized to the liver." | 9.07 | Alternating hepatic intra-arterial floxuridine and fluorouracil: a less toxic regimen for treatment of liver metastases from colorectal cancer. ( Chase, JL; Grobman, BJ; Hohn, DC; Lewis, BJ; Mulvihill, SJ; Rayner, AA; Roh, M; Stagg, RJ; Venook, AP; Warren, RS, 1991) |
| "Seventy-four patients with liver metastasis from proved colorectal primary adenocarcinoma were entered into a prospective, randomized clinical trial to evaluate treatment with intra-arterial floxuridine compared with standard outpatient therapy with fluorouracil delivered by intravenous bolus injection." | 9.06 | Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. ( Fitzgibbons, RJ; Krook, JE; Mailliard, JA; Martin, JK; Nagorney, DM; O'Connell, MJ; Rubin, J; Tschetter, LK; Wieand, HS, 1990) |
| "In 1983, the Northern California Oncology Group (NCOG) instituted a randomized trial of intravenous (IV) versus intraarterial (IA) floxuridine (FUDR) administered via an implantable pump for patients with colorectal cancer metastatic to the liver." | 9.06 | A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. ( Acord, P; Friedman, MA; Hannigan, JF; Hohn, DC; Ignoffo, RJ; Lewis, BJ; Rayner, A; Stagg, RJ, 1989) |
| "Salvage treatment with 5-fluorouracil (5-FU) with or without leucovorin may induce responses in patients with advanced colorectal cancer whose disease progresses after adjuvant therapy with the same drugs." | 8.80 | Is repeated treatment with a 5-fluorouracil-based regimen useful in colorectal cancer? ( Goldberg, RM, 1998) |
| "To evaluate and compare the efficiency and safety of raltitrexed- or floxuridine (FUDR)-based transarterial chemoembolization (TACE) in patients with unresectable colorectal cancer liver metastasis (CRCLM)." | 7.91 | Transarterial chemoembolization with raltitrexed-based or floxuridine-based chemotherapy for unresectable colorectal cancer liver metastasis. ( He, XH; Huang, HZ; Li, GD; Li, WT; Wang, GZ; Wang, Y; Wang, YH; Wei, N; Xu, LC; Zhang, B, 2019) |
| "This study aimed to compare the efficacy and safety of HAI fluoropyrimidine (FUDR)/capecitabine or single capecitabine as first-line treatment for elderly patients with unresectable colorectal liver metastases (CLMs)." | 7.83 | First-line treatment with hepatic arterial infusion plus capecitabine vs capecitabine alone for elderly patients with unresectable colorectal liver metastases. ( Ding, W; Ji, M; Jiang, J; Li, X; Lu, Q; Qiang, W; Shi, L; Wu, C; Wu, J; Zhao, J, 2016) |
| "To clarify the correlation between the expression level of thymidine phosphorylase (TP) and efficacy of doxifluridine (5'-DFUR) and 5-fluorouracil (5-FU), samples from 177 colorectal cancer patients who underwent curative resection were evaluated by immunohistochemical staining using a newly developed monoclonal antibody 1C6-203." | 7.73 | Thymidine phosphorylase expression and efficacy of adjuvant doxifluridine in advanced colorectal cancer patients. ( Hasegawa, R; Hasegawa, S; Koda, K; Miyazaki, M; Oda, K; Seike, K; Takiguchi, N, 2005) |
| "We investigated whether the efficacy of peroral doxifluridine and hepatic arterial 5-FU infusion on synchronous liver metastasis of colorectal cancer could be predicted based on the expression of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) in the primary colorectal lesions." | 7.71 | [Effect of peroral doxifluridine plus hepatic arterial infusion for synchronous liver metastasis of colorectal cancer--correlation with the expression of thymidine phosphorylase and dihydropyrimidine dehydrogenase in primary colorectal cancer lesions]. ( Fujioka, M; Hashimoto, D; Hoshino, T; Inokuma, S; Ishida, H; Ishizuka, N; Matsumoto, Y; Miura, T; Murata, N; Nakada, H; Odaka, A; Ohsawa, T; Takeuchi, I; Yamada, H; Yokoyama, M, 2001) |
| "The results support a role for p53 "hot spot" mutations in colorectal liver metastasis resistance to fluorinated pyrimidines, and suggest that the presence of such mutations may be a contra-indication to treatment of colorectal liver metastases with hepatic arterial floxuridine." | 7.71 | P53 mutation and response to hepatic arterial floxuridine in patients with colorectal liver metastases. ( Allen-Mersh, TG; Feldmann, KA; Ivison, A; Jonas, SK; Khan, ZA; Patel, H; Tarragona, A; Wharton, RQ, 2001) |
| "To confirm our previous kinetic analysis of the mode of cell-killing action of 5-fluorouracil (5-FU), we carried out a flow cytometric analysis with human colorectal cancer DLD-1 cells." | 7.69 | Flow cytometric analysis of cell-killing actions of 5-fluorouracil in human colorectal cancer cells. ( Inaba, M; Mitsuhashi, J, 1994) |
| "To evaluate clinical outcomes when HAI chemotherapy is combined with systemic chemotherapy in patients with unresectable IHC." | 6.94 | Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. ( Allen, PJ; Balachandran, VP; Boerner, T; Boucher, TM; Cercek, A; Chapman, WC; Chou, JF; D'Angelica, MI; DeMatteo, RP; Diaz, LA; Do, RKG; Drebin, JA; Fields, RC; Gönen, M; Harding, JJ; Hauser, HF; Hawkins, WG; Jarnagin, WR; Kemeny, NE; Kingham, TP; Lim, KH; Lowery, MA; Majella Doyle, MB; Reidy-Lagunes, D; Saltz, L; Sanchez-Vega, F; Schultz, N; Strasberg, SM; Tan, BR; Vachharajani, N; Varghese, AM, 2020) |
| "Twenty-seven patients with advanced colorectal cancer were enrolled in this study, and the UGT1A1*28 polymorphism was genotyped before chemotherapy." | 6.75 | Phase I study of irinotecan and doxifluridine for metastatic colorectal cancer focusing on the UGT1A1*28 polymorphism. ( Araki, A; Hazama, S; Hinoda, Y; Kondo, H; Nagashima, A; Oka, M; Okayama, N; Shimizu, R; Yoshida, S; Yoshino, S, 2010) |
| "We investigated 17 colorectal cancer patients' PyNPase and DPD activities in tumor and normal tissues using an enzyme-linked immunosorbent assay (ELISA) to assess their clinical significance as indicators for selecting colorectal cancer patients for 5'-DFUR together with MMC as adjuvant chemotherapy." | 6.73 | Pyrimidine nucleoside phosphorylase and dihydropyrimidine dihydrogenase activities as predictive factors for the efficacy of doxifluridine together with mitomycin C as adjuvant chemotherapy in primary colorectal cancer. ( Higashijima, J; Kurita, N; Miyamoto, H; Miyatani, T; Nishioka, M; Shimada, M; Yoshikawa, K, 2007) |
| "Only patients with colorectal cancer who had evidence of unresectable metastases confined to the liver were eligible." | 6.69 | Sequential intrahepatic fluorodeoxyuridine and systemic fluorouracil plus leucovorin for the treatment of metastatic colorectal cancer confined to the liver. ( Bernath, AM; Bolton, JS; Burch, P; Colon-Otero, G; Fitzgibbons, RJ; Krook, JE; Mailliard, JA; Nagorney, DM; O'Connell, MJ; Schroeder, G, 1998) |
| "All patients had metastatic colorectal cancer, with adjuvant or palliative chemotherapy given to six patients (22%) on schedule A and 12 patients on schedule B (41%)." | 6.69 | Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion. ( Adam, R; Bismuth, H; Dallemagne, B; Focan, C; Focan-Henrard, D; Jasmin, C; Jehaes, C; Kreutz, F; Levi, F; Lobelle, JP; Markiewicz, S; Misset, JL; Weerts, J, 1999) |
| "Doxifluridine (5-dFUR) is a fluoropyrimidine derivative, which is preferentially converted to 5-fluorouracil (5-FU) within tumour tissues." | 6.68 | Doxifluridine in colorectal cancer patients resistant to 5-fluorouracil (5-FU) containing regimens. ( Artale, S; Bajetta, E; Bignami, P; Buzzoni, R; Del Vecchio, M; Di Bartolomeo, M; Magnani, E; Somma, L; Zunino, F, 1997) |
| "In human colorectal cancer cell lines and various animal tumour model systems 5-fluoro-2'-deoxyuridine (FdUrd) is more effective than 5-fluorouracil (5-FU)." | 6.40 | Comparison of 5-fluoro-2'-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer. ( Ackland, SP; Peters, GJ; Rustum, YM; van Groeningen, CJ; van Laar, JA, 1998) |
| "The purpose of this study was to examine the efficacy of a combination treatment of sequential irinotecan and doxifluridine, an intermediate of capecitabine, evaluated by the response rate and safety in patients with metastatic colorectal cancer." | 6.23 | A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer. ( Amano, M; Fukunaga, M; Ikeda, K; Ikeda, M; Ikenaga, M; Ishida, H; Kato, T; Mishima, H; Monden, M; Murata, K; Ohnishi, T; Ota, H; Sakamoto, J; Sekimoto, M; Tominaga, S, 2008) |
| "The purpose was to determine whether adding Pmab versus no Pmab to an adjuvant regimen of hepatic arterial infusion (HAI) of floxuridine (FUDR) plus systemic (SYS) leucovorin, fluorouracil, and irinotecan (FOLFIRI) improves 15-month recurrence-free survival for patients with RAS wild-type colorectal cancer." | 5.41 | A Randomized Phase II Trial of Adjuvant Hepatic Arterial Infusion and Systemic Therapy With or Without Panitumumab After Hepatic Resection of KRAS Wild-type Colorectal Cancer. ( Capanu, M; Chatila, WK; Chou, JF; Connell, LC; D'Angelica, MI; Jarnagin, WR; Kemeny, NE; Kingham, TP; Sanchez-Vega, F; Shi, H, 2021) |
| "In mice bearing human colorectal cancer COLO 205, the antitumor activity of CPT-11 in the combination with 5'-DFUR was additive in all of the examined schedules." | 5.32 | [Optimal dosing schedule in combination therapy with irinotecan and doxifluridine in a human colorectal cancer xenograft model]. ( Ishikawa, T; Ouchi, KF; Tanaka, Y; Yanagisawa, M, 2003) |
| " The mean total dosage was 6." | 5.30 | [Pyrimidine nucleoside phosphorylase activity, 5-fluorouracil concentration and thymidylate synthase inhibition rate in colorectal cancer after oral administration of 5'-doxifluridine]. ( Baba, H; Kohnoe, S; Matsuoka, H; Morita, M; Saito, T; Seo, Y; Taketomi, A; Tomoda, H, 1997) |
| "The benefits from medical treatment in colorectal cancer are limited." | 5.28 | Reversal of resistance to doxifluridine and fluorouracil in metastatic colorectal cancer: the role of high-dose folinic acid. ( Bajetta, E; Colleoni, M; de Braud, F; Nelli, P; Nolè, F; Zilembo, N, 1992) |
| "To determine the maximum tolerated dose (MTD) and preliminary efficacy of concurrent hepatic arterial infusion (HAI) of floxuridine (FUDR) and systemic modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable hepatic metastases from colorectal cancer." | 5.19 | Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer. ( Chen, C; Chen, G; Ding, P; Gu, Y; He, Y; Li, C; Li, W; Li, Y; Lu, Z; Luo, H; Pan, Z; Wan, D; Wang, F; Wang, Z; Wu, X; Xu, R; Yuan, Y; Zhao, M, 2014) |
| "We performed a phase II study of irinotecan with 5'-deoxy-5-fluorouridine (5'-DFUR) for metastatic colorectal cancer based on UDP-glucuronosyltransferase (UGT) 1A1 polymorphism." | 5.17 | UDP-glucuronosyltransferase (UGT) 1A1*28 polymorphism-directed phase II study of irinotecan with 5'-deoxy-5-fluorouridine (5'-DFUR) for metastatic colorectal cancer. ( Araki, A; Eto, R; Hazama, S; Hinoda, Y; Kanekiyo, S; Kondo, H; Nagashima, A; Oka, M; Okayama, N; Shimizu, R; Uchiyama, T; Yamamoto, T; Yoshida, S; Yoshino, S, 2013) |
| "Twenty-nine unresectable colorectal cancer patients were stratified to either ≥70 or <60 years of age, where the disposition of capecitabine and its metabolites were compared." | 5.17 | Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030). ( Albain, KS; Blanke, CD; Coleman, D; Ely, B; Gold, PJ; Gotay, C; Lenz, HJ; Louie, SG; Raghavan, D; Shields, AF, 2013) |
| "The aim of this study was to evaluate the therapeutic efficacy and safety of hepatic arterial infusion (HAI) with irinotecan, oxaliplatin, and floxuridine as a firstline treatment in patients with unresectable liver metastases of colorectal cancer (CRC)." | 5.16 | Hepatic arterial infusion with irinotecan, oxaliplatin, and floxuridine plus systemic chemotherapy as first-line treatment of unresectable liver metastases from colorectal cancer. ( Chen, Y; Liu, Q; Luo, J; Wang, J; Wang, X; Yan, Z, 2012) |
| "In view of a potential gain in anticancer activity in advanced colorectal cancer (ACRC), there has been considerable interest in using a higher than the approved standard dose of capecitabine (CCB) combined with oxaliplatin." | 5.15 | Plasma disposition of capecitabine and its metabolites 5'DFCR and 5'DFUR in a standard and dose-intensified monotherapy regimen. ( Czejka, M; Farkouh, A; Gruenberger, B; Scheithauer, W; Schueller, J, 2011) |
| " Oxaliplatin combined with capecitabine has demonstrated activity in advanced colorectal cancer." | 5.14 | Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) phase II intergroup trial, N9945/CI- ( Alberts, SR; Bolton, JS; Dentchev, T; Lai, LL; Mahoney, MR; Molina, R; Nagorney, DM; O'Connell, MJ; Roh, MS; Schwarz, RE; Smyrk, TC; Wagman, L; Weiland, TL, 2010) |
| "To evaluate the therapeutic efficacy and safety of combination chemotherapy with oxaliplatin, irinotecan and doxifluridine through hepatic arterial infusion (HAI) in patients with unresectable liver metastases of colorectal cancer." | 5.14 | Hepatic arterial infusion with oxaliplatin, irinotecan and doxifluridine for unresectable liver metastases of colorectal cancer. ( Chen, Y; Liu, Q; Luo, J; Wang, J; Wang, X; Yan, Z, 2010) |
| "Our objectives were to determine response rate, time to progression, overall survival and tolerability of novel combination chemotherapy, consisting of irinotecan, high-dose 24-h continuous intravenous infusion of floxuridine and leucovorin in advanced previously untreated colorectal cancer." | 5.12 | A phase II study of irinotecan, high-dose 24-h continuous intravenous infusion of floxuridine and leucovorin (IFLUX) for advanced, previously untreated colorectal cancer. ( Ardalan, B; Franceschi, D; Kozyreva, O; Lima, M; Livingstone, A; Santos, E; Tsai, KT, 2007) |
| "The combination of irinotecan and a fluoropyrimidine has been widely accepted as a treatment for advanced colorectal carcinoma." | 5.11 | Gene expression profiles of colorectal carcinoma in response to neo-adjuvant chemotherapy. ( Hiro, J; Inoue, Y; Kobayashi, M; Kusunoki, M; Miki, C; Mori, K; Shirane, M; Tanaka, K; Yanagi, H, 2004) |
| "Irinotecan (CPT-11) and doxifluridine (5'-DFUR) are active agents against colorectal cancer." | 5.11 | Sequential treatment with irinotecan and doxifluridine: optimal dosing schedule in murine models and in a phase I study for metastatic colorectal cancer. ( Fujimoto-Ouchi, K; Kato, T; Kikkawa, N; Mishima, H; Nishisho, I; Tanaka, Y; Tsujie, M; Tsujinaka, T; Yanagisawa, M, 2005) |
| "The results suggest that, compared with historical controls, high-dose focal liver irradiation with hepatic artery floxuridine prolongs survival in patients with unresectable chemotherapy-refractory metastatic colorectal cancer and primary hepatobiliary tumors." | 5.11 | Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. ( Ben-Josef, E; Dawson, LA; Ensminger, WD; Knol, J; Lawrence, TS; Normolle, D; Pan, C; Tatro, D; Ten Haken, RK; Walker, S, 2005) |
| "This phase II study was designed to evaluate the efficacy and toxicities of oral doxifluridine plus leucovorin as a randomized trial with those of intravenous 5-fluorouracil (5-FU) plus leucovorin in previously untreated metastatic colorectal cancer (CRC)." | 5.10 | Oral doxifluridine plus leucovorin in metastatic colorectal cancer: randomized phase II trial with intravenous 5-fluorouracil plus leucovorin. ( Ahn, JH; Kang, YK; Kim, JC; Kim, JG; Kim, TW; Kim, WK; Lee, JH; Lee, JS; Min, YJ; Yu, CS, 2003) |
| "To assess the relationship between systemic exposure to capecitabine metabolites and parameters of efficacy and safety in patients with advanced or metastatic colorectal cancer from two phase III studies." | 5.10 | Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients. ( Blesch, KS; Burger, HU; Gieschke, R; Reigner, B; Steimer, JL, 2003) |
| "This study was designed to evaluate hepatic arterial infusion of floxuridine (FUDR) in patients with resected hepatic metastases from colorectal cancer." | 5.09 | Phase II evaluation of treatment of complete resection of hepatic metastases from colorectal cancer and adjuvant hepatic arterial infusion of floxuridine: an Eastern Cooperative Oncology Group Study (PB083). ( Berlin, J; Lerner, H; Merrick, HW; Smith, TJ, 1999) |
| "We randomly assigned 156 patients at the time of resection of hepatic metastases from colorectal cancer to receive six cycles of hepatic arterial infusion with floxuridine and dexamethasone plus intravenous fluorouracil, with or without leucovorin, or six weeks of similar systemic therapy alone." | 5.09 | Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. ( Bertino, JR; Blumgart, LH; Brennan, MF; Cohen, AM; Conti, JA; Fong, Y; Huang, Y; Kemeny, N; Shi, W; Stockman, J; Sullivan, D; Turnbull, AD, 1999) |
| "In patients with colorectal cancer, selective high 5-fluorouracil concentration in the cancer tissue could be achieved by a combination of 5'-deoxy-5-fluorouridine and local immunotherapy with a mixture of OK-432 and fibrinogen." | 5.09 | Selective augmentations of intratumoral 5-fluorouracil concentration by local immunotherapy with OK-432 and fibrinogen. ( Amano, M; Haba, A; Monden, M; Monden, T; Ohue, M; Sakita, I; Sekimoto, M; Tamaki, Y; Tomita, N, 2000) |
| " We measured DPD activities represented as DPD protein levels (units/mg protein) and the associated mRNA levels in tumorous and normal tissues from 40 colorectal cancer patients, and we studied the relation to 5-FU concentrations in the same samples after treatment with doxifluridine, a prodrug of 5-FU." | 5.09 | Variations in 5-fluorouracil concentrations of colorectal tissues as compared with dihydropyrimidine dehydrogenase (DPD) enzyme activities and DPD messenger RNA levels. ( Kato, S; Onda, M; Tanaka, N; Tanaka-Nozaki, M, 2001) |
| "We conducted a multi-center study to investigate the usefulness of a combination drug therapy with doxifluridine (5'-DFUR) and mitomycin C (MMC) in colorectal cancer patients with lung metastasis." | 5.09 | [Combination chemotherapy of doxifluridine plus mitomycin C for colorectal lung metastasis--phase II study]. ( Fujita, H; Hiki, Y; Ike, H; Mitomi, T; Otani, Y; Oya, K; Sadahiro, S; Shimada, H; Yamaguchi, S, 2001) |
| "This study was designed to test the activity and feasibility of an all-oral regimen of levo-leucovorin and doxifluridine (dFUR) in the treatment of advanced colorectal cancer and to establish whether the pharmacokinetics of dFUR and fluorouracil (FU) are affected by demographic and/or biologic parameters." | 5.08 | Doxifluridine and leucovorin: an oral treatment combination in advanced colorectal cancer. ( Bajetta, E; Bozzetti, F; Buzzoni, R; Cappuzzo, F; Colleoni, M; Di Bartolomeo, M; Doci, R; Guenzi, A; Somma, L; Stampino, CG, 1995) |
| "These results indicate that suramin is inactive in patients with metastatic colorectal cancer pretreated with fluoropyrimidines." | 5.08 | Suramin in patients with metastatic colorectal cancer pretreated with fluoropyrimidine-based chemotherapy. A phase II study. ( Brunetti, I; Cianci, C; Conte, PF; Danesi, R; Del Tacca, M; Falcone, A; Pfanner, E, 1995) |
| "We conducted a multicentric phase II study on advanced colorectal cancer to determine the efficacy and toxicity of oral treatment with leucovorin (LV) plus doxifluridine (5'DFUR), a novel fluoropyrimidine derivative with proven antitumor activity in different experimental models." | 5.08 | Results of leucovorin and doxifluridine oral regimen in the treatment of metastatic colorectal cancer. ( Agostino, I; Andreoli, F; Bartolini, P; Gemelli, MT; Neri, B; Pantalone, D; Pernice, ML; Scatizzi, M; Siliani, GM, 1998) |
| "This study demonstrates that a home therapy with oral doxifluridine in elderly advanced colorectal cancer patients is feasible, with a relatively low rate of toxicity, and has moderate activity, comparable to that of intravenous 5-fluorouracil." | 5.07 | Oral doxifluridine in elderly patients with metastatic colorectal cancer: a multicenter phase II study. ( Barduagni, M; Bertuccelli, M; Calabresi, F; Carrai, M; Ceribelli, A; Cianci, C; De Marco, S; Falcone, A; Pfanner, E; Ricci, S, 1994) |
| "We studied three new dose schedules of hepatic arterial infusion of floxuridine (FUDR) and leucovorin and update survival analysis of a previously reported trial using these drugs by hepatic arterial infusion for patients with hepatic metastases from colorectal carcinoma." | 5.07 | Hepatic arterial floxuridine and leucovorin for unresectable liver metastases from colorectal carcinoma. New dose schedules and survival update. ( Bertino, JR; Botet, J; Budd, AJ; Chapman, D; Cohen, A; Conti, JA; Kemeny, N; Mazumdar, M; Seiter, K; Sigurdson, ER, 1994) |
| " The purpose of this study was to compare its therapeutic effect with a standard fluorouracil (FU) regimen in patients with locally advanced or metastatic colorectal cancer." | 5.07 | Prospective randomised trial comparing fluorouracil versus doxifluridine for the treatment of advanced colorectal cancer. ( Amadori, D; Bajetta, E; Calabresi, F; Colleoni, M; Comella, G; Lorusso, V; Marangolo, M; Rosso, R; Scanni, A; Sobrero, A, 1993) |
| "This study was designed to determine if hepatic arterial therapy with floxuridine (F), mitomycin, and carmustine (BCNU) (FMB) is superior to hepatic arterial therapy with F alone in previously treated patients with hepatic metastases from colorectal cancer." | 5.07 | Randomized trial of hepatic arterial floxuridine, mitomycin, and carmustine versus floxuridine alone in previously treated patients with liver metastases from colorectal cancer. ( Botet, J; Budd, A; Cohen, A; Conti, JA; Kemeny, N; Niedzwiecki, D; Seiter, K; Sigurdson, ER; Tao, Y, 1993) |
| "Because of possibly better activity against colorectal cancer of 5-fluoro-2'-deoxyuridine [floxuridine (FUdR)] compared to 5-fluorouracil (5-FU), and because of improved therapeutic results of leucovorin (LV) modulation of 5-FU, we carried out a phase II study of systemic FUdR and LV in 5-FU-treated patients with metastatic colorectal cancer." | 5.07 | Phase II study of pulse 5-fluoro-2'-deoxyuridine and leucovorin in advanced colorectal cancer patients previously treated with chemotherapy. ( Bertino, JR; Davis, C; Durivage, HJ; Marsh, JC; O'Hollaren, K; Pasquale, DN; Simonich, SA; Voynick, IM, 1992) |
| "Hepatic intra-arterial (HIA) infusion of floxuridine (FUDR) via an implanted pump has shown promise in the treatment of colorectal cancer metastasized to the liver." | 5.07 | Alternating hepatic intra-arterial floxuridine and fluorouracil: a less toxic regimen for treatment of liver metastases from colorectal cancer. ( Chase, JL; Grobman, BJ; Hohn, DC; Lewis, BJ; Mulvihill, SJ; Rayner, AA; Roh, M; Stagg, RJ; Venook, AP; Warren, RS, 1991) |
| "Seventy-four patients with liver metastasis from proved colorectal primary adenocarcinoma were entered into a prospective, randomized clinical trial to evaluate treatment with intra-arterial floxuridine compared with standard outpatient therapy with fluorouracil delivered by intravenous bolus injection." | 5.06 | Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. ( Fitzgibbons, RJ; Krook, JE; Mailliard, JA; Martin, JK; Nagorney, DM; O'Connell, MJ; Rubin, J; Tschetter, LK; Wieand, HS, 1990) |
| "In 1983, the Northern California Oncology Group (NCOG) instituted a randomized trial of intravenous (IV) versus intraarterial (IA) floxuridine (FUDR) administered via an implantable pump for patients with colorectal cancer metastatic to the liver." | 5.06 | A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. ( Acord, P; Friedman, MA; Hannigan, JF; Hohn, DC; Ignoffo, RJ; Lewis, BJ; Rayner, A; Stagg, RJ, 1989) |
| "Salvage treatment with 5-fluorouracil (5-FU) with or without leucovorin may induce responses in patients with advanced colorectal cancer whose disease progresses after adjuvant therapy with the same drugs." | 4.80 | Is repeated treatment with a 5-fluorouracil-based regimen useful in colorectal cancer? ( Goldberg, RM, 1998) |
| "Since the clinical introduction of 5-fluorouracil (5-FU) in 1958, improvements in the treatment of advanced colorectal cancer have been modest." | 4.79 | Chemotherapy of colorectal cancer: history and new themes. ( Bertino, JR, 1997) |
| "To evaluate and compare the efficiency and safety of raltitrexed- or floxuridine (FUDR)-based transarterial chemoembolization (TACE) in patients with unresectable colorectal cancer liver metastasis (CRCLM)." | 3.91 | Transarterial chemoembolization with raltitrexed-based or floxuridine-based chemotherapy for unresectable colorectal cancer liver metastasis. ( He, XH; Huang, HZ; Li, GD; Li, WT; Wang, GZ; Wang, Y; Wang, YH; Wei, N; Xu, LC; Zhang, B, 2019) |
| "We enrolled patients administered adjuvant capecitabine plus oxaliplatin (CapeOX) for postoperative colorectal cancer (CRC) patients and metastatic CRC patients receiving CapeOX with/without bevacizumab." | 3.91 | Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, and 5-fluorouracil. ( Fujita, KI; Ishida, H; Ishikawa, F; Kubota, Y; Ohkuma, R; Sasaki, Y; Sekido, M; Shibanuma, M; Takahashi, T; Tsunoda, T, 2019) |
| "This study aimed to compare the efficacy and safety of HAI fluoropyrimidine (FUDR)/capecitabine or single capecitabine as first-line treatment for elderly patients with unresectable colorectal liver metastases (CLMs)." | 3.83 | First-line treatment with hepatic arterial infusion plus capecitabine vs capecitabine alone for elderly patients with unresectable colorectal liver metastases. ( Ding, W; Ji, M; Jiang, J; Li, X; Lu, Q; Qiang, W; Shi, L; Wu, C; Wu, J; Zhao, J, 2016) |
| "To explore the changes of anticancer efficiency of 5'-deoxy-5-fluorouridine (5'-DFUR) and 5-fluorouracil (5-Fu) in colorectal cancer cell line HT29 and LS174T cells after transfection of thymidine phosphorylase (TP) cDNA with a lentiviral vector." | 3.81 | [Transfection of thymidine phosphorylase cDNA with lentiviral vector enhances the anticancer effect of 5'-deoxy-5-fluorouridine on colorectal cancer cell lines HT29 and LS174T]. ( Liu, Q; Wang, Q; Ye, D; Zhang, J, 2015) |
| "Capecitabine, designed as a pro-drug to the cytotoxic agent 5-fluorouracil, is widely used in the management of colorectal cancer." | 3.80 | Clinical pharmacokinetics of capecitabine and its metabolites in combination with the monoclonal antibody bevacizumab. ( Buchner, P; Czejka, M; Farkouh, A; Georgopoulos, A; Gruenberger, B; Scheithauer, W; Schueller, J, 2014) |
| "PURPOSE To determine the conversion to resectability in patients with unresectable liver metastases from colorectal cancer treated with hepatic arterial infusion (HAI) plus systemic oxaliplatin and irinotecan (CPT-11)." | 3.75 | Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. ( Capanu, M; D'Angelica, M; Fong, Y; Jarnagin, WR; Kemeny, NE; Melendez, FD; Patel, D; Paty, PB; Schwartz, LH, 2009) |
| "To clarify the correlation between the expression level of thymidine phosphorylase (TP) and efficacy of doxifluridine (5'-DFUR) and 5-fluorouracil (5-FU), samples from 177 colorectal cancer patients who underwent curative resection were evaluated by immunohistochemical staining using a newly developed monoclonal antibody 1C6-203." | 3.73 | Thymidine phosphorylase expression and efficacy of adjuvant doxifluridine in advanced colorectal cancer patients. ( Hasegawa, R; Hasegawa, S; Koda, K; Miyazaki, M; Oda, K; Seike, K; Takiguchi, N, 2005) |
| " Our study population was patients who had undergone arterial mapping in preparation for placement of a hepatic arterial floxuridine infusion pump for treatment of metastatic hepatic colorectal carcinoma." | 3.72 | Multidetector CT arteriography with volumetric three-dimensional rendering to evaluate patients with metastatic colorectal disease for placement of a floxuridine infusion pump. ( Brancatelli, G; Federle, MP; Geller, DA; Kapoor, V; Katyal, S; Marsh, JW, 2003) |
| "Hepatic intra-arterial infusion chemotherapy of 5-fluorouracil (5-FU) or fluorodeoxyuridine (FUDR) has been a treatment option for liver metastasis from colorectal cancer." | 3.72 | Pharmacokinetics of 5-fluorouracil following hepatic intra-arterial infusion in a VX2 hepatic metastasis model. ( Ishikawa, K; Makuuchi, H; Masuda, T; Murayama, C; Nakamura, T; Sadahiro, S; Suzuki, T; Tanaka, Y; Yasuda, S, 2003) |
| "In metastatic colorectal cancer the oral 5-fluorouracil (5FU) prodrug capecitabine is used with increasing frequency as an alternative to i." | 3.72 | In vivo monitoring of capecitabine metabolism in human liver by 19fluorine magnetic resonance spectroscopy at 1.5 and 3 Tesla field strength. ( Heerschap, A; Kamm, YJ; Klomp, DW; Punt, CJ; van Laarhoven, HW, 2003) |
| "The present results suggest that coupling to lactosaminated albumin might improve the effect of floxuridine in adjuvant chemotherapy of colorectal cancer by exposing the cells of liver micrometastases (nourished by hepatic sinusoids) to enhanced drug concentrations." | 3.71 | Floxuridine coupling with lactosaminated human albumin to increase drug efficacy on liver micrometastases. ( Busi, C; Di Stefano, G; Fiume, L, 2002) |
| "We investigated whether the efficacy of peroral doxifluridine and hepatic arterial 5-FU infusion on synchronous liver metastasis of colorectal cancer could be predicted based on the expression of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) in the primary colorectal lesions." | 3.71 | [Effect of peroral doxifluridine plus hepatic arterial infusion for synchronous liver metastasis of colorectal cancer--correlation with the expression of thymidine phosphorylase and dihydropyrimidine dehydrogenase in primary colorectal cancer lesions]. ( Fujioka, M; Hashimoto, D; Hoshino, T; Inokuma, S; Ishida, H; Ishizuka, N; Matsumoto, Y; Miura, T; Murata, N; Nakada, H; Odaka, A; Ohsawa, T; Takeuchi, I; Yamada, H; Yokoyama, M, 2001) |
| "The results support a role for p53 "hot spot" mutations in colorectal liver metastasis resistance to fluorinated pyrimidines, and suggest that the presence of such mutations may be a contra-indication to treatment of colorectal liver metastases with hepatic arterial floxuridine." | 3.71 | P53 mutation and response to hepatic arterial floxuridine in patients with colorectal liver metastases. ( Allen-Mersh, TG; Feldmann, KA; Ivison, A; Jonas, SK; Khan, ZA; Patel, H; Tarragona, A; Wharton, RQ, 2001) |
| "To confirm our previous kinetic analysis of the mode of cell-killing action of 5-fluorouracil (5-FU), we carried out a flow cytometric analysis with human colorectal cancer DLD-1 cells." | 3.69 | Flow cytometric analysis of cell-killing actions of 5-fluorouracil in human colorectal cancer cells. ( Inaba, M; Mitsuhashi, J, 1994) |
| "Based on laboratory studies showing enhanced cytotoxicity of floxuridine (FUDR) when used with high doses of leucovorin (LV), a pilot study of FUDR and LV through an implantable pump was initiated for the treatment of hepatic metastases from colorectal cancer." | 3.68 | Continuous intrahepatic infusion of floxuridine and leucovorin through an implantable pump for the treatment of hepatic metastases from colorectal carcinoma. ( Bertino, JR; Botet, J; Cohen, A; Kemeny, N; Oderman, P; Sigurdson, ER, 1990) |
| "To evaluate clinical outcomes when HAI chemotherapy is combined with systemic chemotherapy in patients with unresectable IHC." | 2.94 | Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. ( Allen, PJ; Balachandran, VP; Boerner, T; Boucher, TM; Cercek, A; Chapman, WC; Chou, JF; D'Angelica, MI; DeMatteo, RP; Diaz, LA; Do, RKG; Drebin, JA; Fields, RC; Gönen, M; Harding, JJ; Hauser, HF; Hawkins, WG; Jarnagin, WR; Kemeny, NE; Kingham, TP; Lim, KH; Lowery, MA; Majella Doyle, MB; Reidy-Lagunes, D; Saltz, L; Sanchez-Vega, F; Schultz, N; Strasberg, SM; Tan, BR; Vachharajani, N; Varghese, AM, 2020) |
| "Twenty-seven patients with advanced colorectal cancer were enrolled in this study, and the UGT1A1*28 polymorphism was genotyped before chemotherapy." | 2.75 | Phase I study of irinotecan and doxifluridine for metastatic colorectal cancer focusing on the UGT1A1*28 polymorphism. ( Araki, A; Hazama, S; Hinoda, Y; Kondo, H; Nagashima, A; Oka, M; Okayama, N; Shimizu, R; Yoshida, S; Yoshino, S, 2010) |
| "Subjects were 239 patients with colorectal cancer who underwent curative resection surgery from December 1994 to March 1997(Stage I-III b)." | 2.74 | [A randomized controlled trial of postoperative adjuvant chemotherapy for colorectal cancer-optimal duration of the treatment]. ( Abe, R; Fujiwara, H; Fukuyama, N; Hirano, T; Hirata, K; Hotokezaka, M; Imamura, T; Ito, H; Iwashita, A; Kato, H; Konomi, K; Kuroki, N; Miyazaki, R; Miyazaki, Y; Nakahara, S; Nakano, S; Sakamoto, Y; Shimokobe, T; Shiraishi, M; Terasaka, R, 2009) |
| "We investigated 17 colorectal cancer patients' PyNPase and DPD activities in tumor and normal tissues using an enzyme-linked immunosorbent assay (ELISA) to assess their clinical significance as indicators for selecting colorectal cancer patients for 5'-DFUR together with MMC as adjuvant chemotherapy." | 2.73 | Pyrimidine nucleoside phosphorylase and dihydropyrimidine dihydrogenase activities as predictive factors for the efficacy of doxifluridine together with mitomycin C as adjuvant chemotherapy in primary colorectal cancer. ( Higashijima, J; Kurita, N; Miyamoto, H; Miyatani, T; Nishioka, M; Shimada, M; Yoshikawa, K, 2007) |
| "Doxifluridine (5'-DFUR) is an intermediate of capecitabine approved in Europe and USA to treat metastatic colorectal cancer." | 2.71 | A randomized controlled trial of postoperative adjuvant immunochemotherapy for colorectal cancer with oral medicines. ( Koda, K; Kodaira, S; Miyazaki, M; Nakazato, H; Ogawa, K; Saito, N; Sarashina, H; Suwa, T; Suzuki, M; Watanabe, S, 2003) |
| "Most colorectal cancers metastatic to the liver are resistant to chemotherapy and are not amenable to surgical resection." | 2.70 | Systemic irinotecan or regional floxuridine chemotherapy prolongs survival after hepatic cryosurgery in patients with metastatic colon cancer refractory to 5-fluorouracil. ( Bilchik, AJ; Chawla, SP; Chung, MH; Foshag, LJ; Ramming, KP; Rose, DM; Stern, SS; Wood, TF, 2001) |
| "Unresectable colorectal liver metastases are a significant clinical problem." | 2.70 | Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. ( Alexander, HR; Bartlett, DL; Figg, WD; Fraker, DL; Libutti, SK, 2001) |
| "47%, P = 0." | 2.70 | Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. ( Anderson, J; Burton, M; Gebski, V; Gray, B; Hope, M; Moroz, P; Van Hazel, G, 2001) |
| "Patients with one to three potentially resectable metastases were randomized preoperatively to receive no further therapy (control arm, 56 patients) or postoperative hepatic arterial floxuridine combined with intravenous continuous-infusion fluorouracil (chemotherapy arm, 53 patients)." | 2.70 | Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy--an intergroup study. ( Adak, S; Benson, AB; Gray, B; Kemeny, MM; Lipsitz, S; Macdonald, JS; O'Dwyer, PJ; Sigurdson, ER; Smith, T, 2002) |
| "Only patients with colorectal cancer who had evidence of unresectable metastases confined to the liver were eligible." | 2.69 | Sequential intrahepatic fluorodeoxyuridine and systemic fluorouracil plus leucovorin for the treatment of metastatic colorectal cancer confined to the liver. ( Bernath, AM; Bolton, JS; Burch, P; Colon-Otero, G; Fitzgibbons, RJ; Krook, JE; Mailliard, JA; Nagorney, DM; O'Connell, MJ; Schroeder, G, 1998) |
| "All patients had metastatic colorectal cancer, with adjuvant or palliative chemotherapy given to six patients (22%) on schedule A and 12 patients on schedule B (41%)." | 2.69 | Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion. ( Adam, R; Bismuth, H; Dallemagne, B; Focan, C; Focan-Henrard, D; Jasmin, C; Jehaes, C; Kreutz, F; Levi, F; Lobelle, JP; Markiewicz, S; Misset, JL; Weerts, J, 1999) |
| " As a result, the extent of toxicity of cancer chemotherapy varies by 50% or more according to dosing time in mice or rats." | 2.68 | [Chrono-chemotherapy and dose intensity]. ( Lévi, F, 1995) |
| "Patients with far advanced colorectal cancers received chemotherapy consisting of low-dose cyclophosphamide (LDCY) 333 mg/m2 every four weeks intravenously and by oral administration of 5'-DFUR (a masked compound of 5-Fluorouracil)." | 2.68 | Effect of low dose cyclophosphamide on the synthesis of acute phase protein and its significance for cancer chemotherapy. ( Fujiwara, T; Hizuta, A; Iwagaki, H; Orita, K; Perdomo, JA; Tanaka, N, 1996) |
| "Doxifluridine (5-dFUR) is a fluoropyrimidine derivative that has been shown to be active on a variety of solid tumors." | 2.68 | Randomized phase II noncomparative trial of oral and intravenous doxifluridine plus levo-leucovorin in untreated patients with advanced colorectal carcinoma. ( Bajetta, E; Bordogna, G; Comella, G; Di Bartolomeo, M; Gebbia, V; Moreschi, M; Scanni, A; Somma, L; Stampino, CG; Turci, D, 1996) |
| "Doxifluridine (5-dFUR) is a fluoropyrimidine derivative, which is preferentially converted to 5-fluorouracil (5-FU) within tumour tissues." | 2.68 | Doxifluridine in colorectal cancer patients resistant to 5-fluorouracil (5-FU) containing regimens. ( Artale, S; Bajetta, E; Bignami, P; Buzzoni, R; Del Vecchio, M; Di Bartolomeo, M; Magnani, E; Somma, L; Zunino, F, 1997) |
| "Twenty-one stomach cancer patients and 34 colorectal cancer patients were registered in the study." | 2.67 | [Study of 5'-DFUR treatment as postoperative adjuvant chemotherapy for stomach and colorectal cancer. Tokai GATS Group (pilot study)]. ( Hachisuka, K; Honda, H; Honda, K; Maeda, A; Nakazato, H; Tsuruga, N; Yamaguchi, A; Yoshizaki, S; Yura, J, 1994) |
| " The dosage was 0." | 2.66 | Regional chemotherapy for hepatic metastases of colorectal carcinoma (continuous intraarterial versus continuous intraarterial/intravenous therapy). Results of a controlled clinical trial. ( Beger, GH; Bittner, R; Gaus, W; Roscher, R; Safi, F; Schuhmacher, K, 1989) |
| "Dipyridamole (DP) has previously been studied both in vitro and in vivo in combination with various anti-metabolites, including methotrexate and 5-fluorouracil (5FU)." | 2.66 | Effect of dipyridamole on fluorodeoxyuridine cytotoxicity in vitro and in cancer patients. ( Alberts, DS; Buzaid, AC; Einspahr, J; Garewal, HS; Mosley, K; Peng, YM; Spears, CP; Tutsch, K, 1989) |
| "Treatment with eniluracil with oral 5-FU was associated with inferior PFS and OS among participants treated with palliative intent for CRC, and eniluracil is no longer being developed." | 2.55 | Oral versus intravenous fluoropyrimidines for colorectal cancer. ( Chionh, F; Lau, D; Price, T; Tebbutt, N; Yeung, Y, 2017) |
| "A form of non-alcoholic steatohepatitis (NASH) related to chemotherapy and otherwise known as chemotherapy-associated steatohepatitis (CASH) is closely linked to irinotecan-based therapy and is associated with inferior outcomes following hepatic surgery mainly due to hepatic insufficiency and poor regeneration." | 2.45 | Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases. ( Khan, AZ; Makuuchi, M; Morris-Stiff, G, 2009) |
| "Resectability of liver-limited colorectal cancer metastases should be considered as an endpoint for all patients." | 2.44 | Regional chemotherapy for liver-limited metastatic colorectal cancer. ( Healey-Bird, BR; Kemeny, NE; Power, DG, 2008) |
| "Colorectal cancer is a leading cause of cancer death world-wide." | 2.42 | Review article: colorectal cancer chemotherapy. ( Gill, S; Goldberg, RM; Thomas, RR, 2003) |
| "Patients with colorectal cancer commonly succumb to the sequelae of hepatic metastases." | 2.42 | Hepatic arterial infusion chemotherapy for metastatic colorectal cancer: a concise overview. ( Barber, FD; Kurzrock, R; Mavligit, G, 2004) |
| "Progression of colorectal cancer can occur primarily isolated in the liver." | 2.41 | Relevance of locoregional chemotherapy in patients with liver metastases from colorectal primaries. ( Gog, C; Heinrich, S; Lorenz, M; Müller, HH; Petrowsky, H; Staib-Sebler, E; Vetter, G, 2000) |
| "In advanced colorectal cancer, liver metastases are a major problem." | 2.41 | Hepatic arterial chemotherapy for colorectal cancer metastatic to the liver. ( Giaccone, G; Pinedo, HM; van Groeningen, CJ; van Riel, JM, 2000) |
| "Treatment of advanced colorectal cancer has progressed substantially." | 2.41 | Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. ( Burzykowski, T; Buyse, M; Carlson, RW; Molenberghs, G; Piedbois, P; Thirion, P, 2000) |
| " Fluorodeoxyuridine (FUDR) or 5-fluorouracil (5-FU) was used as the agent and a total dosage of 10-20 g was administered for 6-12 months in most studies." | 2.41 | [The role of prophylactic hepatic arterial infusion chemotherapy after potentially curative resection of hepatic metastases from colorectal cancer]. ( Monden, T; Tono, T, 2000) |
| "Targeted treatment of colorectal cancer based on TS quantitation has thus been hypothesized similar to the use of hormone receptor in breast cancer." | 2.41 | Thymidylate Synthase expression as a predictor of clinical response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer. ( Aschele, C; Lonardi, S; Monfardini, S, 2002) |
| "Approximately 20% of patients with colorectal cancer die of metastases confined to the liver." | 2.40 | Economic implications of hepatic arterial infusion chemotherapy in treatment of nonresectable colorectal liver metastases. Meta-Analysis Group in Cancer. ( Allen-Mersh, TG; Buyse, M; Carlson, R; Chang, AE; Durand-Zaleski, I; Fagniez, PL; Kemeny, MM; Le Bourgeois, JP; O'Connell, MJ; Piedbois, P; Roche, B; Rougier, P; Sondak, VK, 1997) |
| "Approximately 50% of patients with colorectal cancer develop locally recurrent or distant metastatic disease during the course of their illness and eventually die." | 2.40 | Chemotherapy for the treatment of patients with metastatic colorectal cancer: an overview. ( Borud, K; Isacoff, WH, 1997) |
| "In human colorectal cancer cell lines and various animal tumour model systems 5-fluoro-2'-deoxyuridine (FdUrd) is more effective than 5-fluorouracil (5-FU)." | 2.40 | Comparison of 5-fluoro-2'-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer. ( Ackland, SP; Peters, GJ; Rustum, YM; van Groeningen, CJ; van Laar, JA, 1998) |
| "Analysis of 98 colorectal cancers revealed that PyNPase was as high as 70." | 2.40 | [PyNPase expression and cancer progression in the colorectum]. ( Amano, M; Haba, A; Ikeda, K; Izawa, H; Kanoh, T; Monden, M; Monden, T; Ohnishi, T; Okamura, J; Sekimoro, M; Tomita, N; Tsujie, M, 1998) |
| "Fifty per cent of patients with colorectal cancer develop hepatic metastases but only a minority are candidates for potentially curative surgical resection." | 2.39 | Hepatic artery chemotherapy for colorectal liver metastases. ( Jorgensen, JO; McCall, JL; Morris, DL, 1995) |
| "The treatment of advanced colorectal cancer has improved in recent years." | 2.38 | Recent advances in the treatment of advanced colorectal cancer. ( Ahlgren, JD; Anderson, N; Kemeny, N; Lokich, JJ, 1993) |
| "A floxuridine assay with a lower boundary of detection of 0." | 1.91 | Systemic exposure of floxuridine after hepatic arterial infusion pump chemotherapy with floxuridine in patients with resected colorectal liver metastases. ( Bruijn, P; Buisman, FE; Doorn, LV; Doornebosch, PG; Filipe, WF; Grootscholten, C; Grünhagen, DJ; Holster, JJ; Homs, MYV; IJzerman, NS; Koerkamp, BG; Kok, NFM; Koolen, SLW; Kuhlmann, KFD; Mathijssen, RHJ; van Bommel, CPE; Verhoef, C, 2023) |
| " Medical oncology experience in floxuridine dosing is critical in maximizing the treatment doses and the number of cycles administered while avoiding biliary toxicity." | 1.91 | Starting a successful hepatic artery infusion pump program: A practical guide. ( Barry-Hundeyin, M; Cavnar, MJ; Ellis, CS; Gholami, S; Kim, J; McDonald, HG; Pandalai, PK; Patel, RA, 2023) |
| "Sarcopenia was prevalent (48%) and was associated with a worse survival (HR 2." | 1.48 | Implementation and early outcomes for a surgeon-directed hepatic arterial infusion pump program for colorectal liver metastases. ( Abdel-Misih, S; Beal, EW; Bloomston, M; Chafitz, A; Chakedis, J; Davidson, G; Dillhoff, M; Galo, J; Pawlik, TM; Reardon, J; Schmidt, CR; Sun, S, 2018) |
| " This study aimed to compare the overall survival (OS) of HAI-FUDR in combination with modern systemic CT versus modern systemic CT alone in patients with IU-CRCLM." | 1.46 | Hepatic Arterial Infusion in Combination with Modern Systemic Chemotherapy is Associated with Improved Survival Compared with Modern Systemic Chemotherapy Alone in Patients with Isolated Unresectable Colorectal Liver Metastases: A Case-Control Study. ( Bahary, N; Bartlett, DL; Choudry, MH; Clifford, AK; Dhir, M; Hogg, ME; Holtzman, MP; Jones, HL; Perkins, S; Pingpank, JF; Shuai, Y; Steve, J; Zeh, HJ; Zureikat, AH, 2017) |
| " In the present study, to address this concern, we proposed a novel strategy of preparing self-assembled nanoparticles from amphiphilic drug-drug conjugate for synergistic combination chemotherapy." | 1.42 | Synergistic Combination Chemotherapy of Camptothecin and Floxuridine through Self-Assembly of Amphiphilic Drug-Drug Conjugate. ( Hu, M; Huang, P; Su, Y; Wang, Y; Yan, D; Zhou, L; Zhu, X, 2015) |
| "In all three studies, the incidence of hyperbilirubinemia and biliary stent placement within 1 year of treatment was increased with the addition of Bev." | 1.40 | Floxuridine hepatic arterial infusion associated biliary toxicity is increased by concurrent administration of systemic bevacizumab. ( Allen, P; Capanu, M; Cercek, A; D'Angelica, M; DeMatteo, RP; Fong, Y; Gewirtz, A; Jarnagin, WR; Kemeny, NE; Patel, D; Power, D, 2014) |
| "The data on 307 patients with colorectal cancer at stage II or III, who underwent potentially curative resection with lymphadenectomy, were reviewed." | 1.33 | The MMP-9 expression determined the efficacy of postoperative adjuvant chemotherapy using oral fluoropyrimidines in stage II or III colorectal cancer. ( Ikeda, S; Ishibashi, N; Matono, K; Mizobe, T; Ogata, Y; Ogo, S; Ohkita, A; Ozasa, H; Sasatomi, T; Shirouzu, K, 2006) |
| "Experimentally, we studied a diploid colorectal cancer line heterozygous at TS to mimic three common TS genotypes of cancers." | 1.33 | Genomic copy number changes affecting the thymidylate synthase (TYMS) gene in cancer: a model for patient classification to aid fluoropyrimidine therapy. ( Brody, JR; Gallmeier, E; Hucl, T; Kern, SE; Murphy, KM; Winter, JM, 2006) |
| "In mice bearing human colorectal cancer COLO 205, the antitumor activity of CPT-11 in the combination with 5'-DFUR was additive in all of the examined schedules." | 1.32 | [Optimal dosing schedule in combination therapy with irinotecan and doxifluridine in a human colorectal cancer xenograft model]. ( Ishikawa, T; Ouchi, KF; Tanaka, Y; Yanagisawa, M, 2003) |
| "Its efficacy for lung metastases from colorectal cancer is known." | 1.30 | [PyNPase activity in primary and metastatic colorectal cancer]. ( Doi, O; Furukawa, H; Hiratsuka, M; Imaoka, S; Ishikawa, O; Iwanaga, T; Kabuto, T; Kameyama, M; Nakamori, S; Ohigashi, H; Sasaki, Y; Yasuda, T; Yokouchi, H, 1997) |
| " The mean total dosage was 6." | 1.30 | [Pyrimidine nucleoside phosphorylase activity, 5-fluorouracil concentration and thymidylate synthase inhibition rate in colorectal cancer after oral administration of 5'-doxifluridine]. ( Baba, H; Kohnoe, S; Matsuoka, H; Morita, M; Saito, T; Seo, Y; Taketomi, A; Tomoda, H, 1997) |
| "Eleven colorectal cancer patients underwent hepatic resection for liver metastasis." | 1.30 | [Adjuvant intra-arterial chemotherapy with gastrin receptor antagonist after hepatic resection in colorectal cancer metastasis]. ( Furukawa, H; Hiratsuka, M; Imaoka, S; Ishikawa, O; Kabuto, T; Kameyama, M; Murata, K; Nakano, H; Ohigashi, H; Sasaki, Y; Tsugawa, T; Yasuda, T, 1998) |
| "Three patients with colorectal cancer and pulmonary metastasis who had previously undergone surgical treatment, were treated by combination chemotherapy with CDDP and 5-FU regimen, but the growth of the metastatic tumor could not be controlled finally." | 1.30 | [Three cases of colorectal cancer with lung metastasis successfully treated with combination chemotherapy using 5'-DFUR and MMC]. ( Horie, H; Hosoya, Y; Ishizuka, T; Kanazawa, K; Kashiwagi, H; Kojima, M; Konishi, H; Shitou, K, 1998) |
| " These results provide a rationale for using short duration of FUdR in combination with other drugs." | 1.29 | Short-term intrahepatic FUdR infusion combined with bolus mitomycin C: reduced risk for developing drug resistance. ( Arisawa, Y; Dalton, RR; Sigurdson, ER; Sutanto-Ward, E, 1994) |
| "Fifty-three patients with advanced colorectal cancer were given single oral doses of 5'-DFUR, 400 mg/body, preoperatively to assess the pharmacokinetics of 5'-DFUR in the patients with colorectal cancer and to investigate schedules for 5'-DFUR treatment." | 1.29 | [Study on the relationship between concentrations of 5-FU and PyNPase activity in tumor tissue during oral 5'-DFUR treatment in patients with advanced colorectal cancer]. ( Hanyu, F; Hayashi, T; Igarashi, T; Suzuki, M; Watanabe, K; Yoshida, K, 1994) |
| " Pharmacokinetic evaluation demonstrated that ILP at 21 mg/mL maximally elevated total lung FUDR and 5-fluorouracil levels (508." | 1.29 | Isolated lung perfusion with FUDR in the rat: pharmacokinetics and survival. ( Burt, ME; Ellis, JL; Lenert, JT; Nawata, S; Ng, B; Port, JL, 1996) |
| "The goals of this study of a hepatic arterial infusion (HAI) regimen of alternating floxuridine and 5-fluorouracil were to evaluate the treatment-related toxic effects, the antitumor response rate, and patient survival." | 1.29 | Alternating floxuridine and 5-fluorouracil hepatic arterial chemotherapy for colorectal liver metastases minimizes biliary toxicity. ( Chase, JL; Curley, SA; Davidson, BS; DuBrow, RA; Hohn, DC; Izzo, F; Patt, Y, 1996) |
| "The benefits from medical treatment in colorectal cancer are limited." | 1.28 | Reversal of resistance to doxifluridine and fluorouracil in metastatic colorectal cancer: the role of high-dose folinic acid. ( Bajetta, E; Colleoni, M; de Braud, F; Nelli, P; Nolè, F; Zilembo, N, 1992) |
| " This was deemed due to the small dosage and a short duration of 5'-DFUR." | 1.28 | [A study on preoperative administration of doxifluridine in carcinoma of the colon and rectum]. ( Harada, T; Hirano, M; Kikkawa, H; Masuda, S; Matsu, T; Saito, H; Sakatoku, M; Tatsuzawa, T, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 27 (9.31) | 18.7374 |
| 1990's | 117 (40.34) | 18.2507 |
| 2000's | 99 (34.14) | 29.6817 |
| 2010's | 40 (13.79) | 24.3611 |
| 2020's | 7 (2.41) | 2.80 |
| Authors | Studies |
|---|---|
| Walker, BS | 1 |
| Billingsley, KG | 1 |
| Sutton, TL | 1 |
| Kolbeck, KJ | 1 |
| Korngold, EK | 1 |
| Nabavizadeh, N | 1 |
| Dewey, EN | 1 |
| Herzig, DO | 1 |
| Lopez, CD | 1 |
| Mayo, SC | 1 |
| Elijah, J | 1 |
| Schepers, AJ | 1 |
| Krauss, JC | 1 |
| McDevitt, RL | 1 |
| IJzerman, NS | 2 |
| Filipe, WF | 2 |
| Bruijn, P | 1 |
| Buisman, FE | 2 |
| Doorn, LV | 1 |
| Doornebosch, PG | 2 |
| Holster, JJ | 1 |
| Grootscholten, C | 2 |
| Grünhagen, DJ | 2 |
| van Bommel, CPE | 1 |
| Homs, MYV | 2 |
| Kok, NFM | 2 |
| Verhoef, C | 2 |
| Koerkamp, BG | 1 |
| Kuhlmann, KFD | 2 |
| Mathijssen, RHJ | 2 |
| Koolen, SLW | 1 |
| McDonald, HG | 1 |
| Patel, RA | 1 |
| Ellis, CS | 1 |
| Gholami, S | 1 |
| Barry-Hundeyin, M | 1 |
| Pandalai, PK | 1 |
| Kim, J | 1 |
| Cavnar, MJ | 1 |
| Cercek, A | 6 |
| Boerner, T | 1 |
| Tan, BR | 1 |
| Chou, JF | 5 |
| Gönen, M | 4 |
| Boucher, TM | 3 |
| Hauser, HF | 1 |
| Do, RKG | 1 |
| Lowery, MA | 1 |
| Harding, JJ | 1 |
| Varghese, AM | 1 |
| Reidy-Lagunes, D | 2 |
| Saltz, L | 1 |
| Schultz, N | 1 |
| Kingham, TP | 4 |
| D'Angelica, MI | 7 |
| DeMatteo, RP | 7 |
| Drebin, JA | 1 |
| Allen, PJ | 5 |
| Balachandran, VP | 1 |
| Lim, KH | 2 |
| Sanchez-Vega, F | 2 |
| Vachharajani, N | 1 |
| Majella Doyle, MB | 1 |
| Fields, RC | 1 |
| Hawkins, WG | 1 |
| Strasberg, SM | 1 |
| Chapman, WC | 1 |
| Diaz, LA | 1 |
| Kemeny, NE | 13 |
| Jarnagin, WR | 10 |
| Christenson, ES | 1 |
| Gizzi, A | 1 |
| Cui, J | 1 |
| Egleston, M | 1 |
| Seamon, KJ | 1 |
| DePasquale, M | 1 |
| Orris, B | 1 |
| Park, BH | 1 |
| Stivers, JT | 1 |
| Capanu, M | 7 |
| Chatila, WK | 1 |
| Shi, H | 1 |
| Connell, LC | 2 |
| Chionh, F | 1 |
| Lau, D | 1 |
| Yeung, Y | 1 |
| Price, T | 2 |
| Tebbutt, N | 1 |
| Dhir, M | 2 |
| Zenati, MS | 1 |
| Jones, HL | 2 |
| Bartlett, DL | 3 |
| Choudry, MHA | 1 |
| Pingpank, JF | 2 |
| Holtzman, MP | 2 |
| Bahary, N | 2 |
| Hogg, ME | 2 |
| Zeh, HJ | 2 |
| Geller, DA | 2 |
| Wallis Marsh, J | 1 |
| Tsung, A | 1 |
| Zureikat, AH | 2 |
| Céspedes, MV | 1 |
| Unzueta, U | 1 |
| Aviñó, A | 1 |
| Gallardo, A | 1 |
| Álamo, P | 1 |
| Sala, R | 1 |
| Sánchez-Chardi, A | 1 |
| Casanova, I | 1 |
| Mangues, MA | 1 |
| Lopez-Pousa, A | 1 |
| Eritja, R | 1 |
| Villaverde, A | 1 |
| Vázquez, E | 1 |
| Mangues, R | 1 |
| Wei, N | 1 |
| Zhang, B | 1 |
| Wang, Y | 2 |
| He, XH | 1 |
| Xu, LC | 1 |
| Li, GD | 1 |
| Wang, YH | 1 |
| Wang, GZ | 1 |
| Huang, HZ | 1 |
| Li, WT | 1 |
| Chakedis, J | 1 |
| Beal, EW | 1 |
| Sun, S | 1 |
| Galo, J | 1 |
| Chafitz, A | 1 |
| Davidson, G | 1 |
| Reardon, J | 1 |
| Dillhoff, M | 1 |
| Pawlik, TM | 1 |
| Abdel-Misih, S | 1 |
| Bloomston, M | 1 |
| Schmidt, CR | 1 |
| Bennink, RJ | 1 |
| Besselink, MGH | 1 |
| Borel Rinkes, IHM | 1 |
| Bruijnen, RCG | 1 |
| van Delden, OM | 1 |
| Donswijk, ML | 1 |
| van Doorn, L | 1 |
| Emmering, J | 1 |
| Erdmann, JI | 1 |
| Hagendoorn, J | 1 |
| Klompenhouwer, EG | 1 |
| Koolen, S | 1 |
| Kuiper, MC | 1 |
| Lam, MGE | 1 |
| Moelker, A | 1 |
| Oomen-de Hoop, E | 1 |
| Punt, CJA | 1 |
| Te Riele, WW | 1 |
| Roodhart, JML | 1 |
| Swijnenburg, RJ | 1 |
| Prevoo, W | 1 |
| Tanis, PJ | 1 |
| Vermaas, M | 1 |
| Versleijen, MWJ | 1 |
| Veuger, FP | 1 |
| Weterman, MJ | 1 |
| Groot Koerkamp, B | 1 |
| Sekido, M | 1 |
| Fujita, KI | 1 |
| Kubota, Y | 1 |
| Ishida, H | 3 |
| Takahashi, T | 2 |
| Ohkuma, R | 1 |
| Tsunoda, T | 1 |
| Ishikawa, F | 1 |
| Shibanuma, M | 1 |
| Sasaki, Y | 4 |
| Kanekiyo, S | 1 |
| Hazama, S | 2 |
| Kondo, H | 2 |
| Nagashima, A | 2 |
| Eto, R | 1 |
| Yoshida, S | 2 |
| Shimizu, R | 2 |
| Araki, A | 2 |
| Yamamoto, T | 1 |
| Uchiyama, T | 1 |
| Yoshino, S | 2 |
| Okayama, N | 2 |
| Hinoda, Y | 2 |
| Oka, M | 2 |
| Louie, SG | 1 |
| Ely, B | 1 |
| Lenz, HJ | 2 |
| Albain, KS | 1 |
| Gotay, C | 1 |
| Coleman, D | 1 |
| Raghavan, D | 1 |
| Shields, AF | 1 |
| Gold, PJ | 1 |
| Blanke, CD | 1 |
| D'Angelica, M | 5 |
| Power, D | 1 |
| Gewirtz, A | 1 |
| Patel, D | 2 |
| Allen, P | 1 |
| Fong, Y | 10 |
| Allard, MA | 1 |
| Malka, D | 1 |
| DʼAngelica, MI | 1 |
| Correa-Gallego, C | 1 |
| Paty, PB | 4 |
| Gewirtz, AN | 1 |
| Kemeny, N | 17 |
| Li, S | 1 |
| He, N | 1 |
| Li, W | 2 |
| Wu, PH | 1 |
| Strobel, O | 1 |
| Büchler, MW | 1 |
| Schreiber, V | 1 |
| Kitzmueller, M | 1 |
| Poxhofer, M | 1 |
| Gintersdorfer, S | 1 |
| Neudorfer, C | 1 |
| Lichtneckert, M | 1 |
| Dittrich, C | 1 |
| Czejka, M | 3 |
| Farkouh, A | 2 |
| Scheithauer, W | 2 |
| Buchner, P | 1 |
| Georgopoulos, A | 1 |
| Schueller, J | 2 |
| Gruenberger, B | 2 |
| Li, C | 1 |
| Gu, Y | 1 |
| Zhao, M | 1 |
| Yuan, Y | 1 |
| Wang, F | 1 |
| Wang, Z | 1 |
| Luo, H | 1 |
| Chen, C | 1 |
| Chen, G | 1 |
| Ding, P | 1 |
| Wu, X | 1 |
| Lu, Z | 1 |
| Pan, Z | 1 |
| Xu, R | 1 |
| He, Y | 1 |
| Wan, D | 1 |
| Li, Y | 1 |
| Ye, D | 1 |
| Wang, Q | 1 |
| Zhang, J | 1 |
| Liu, Q | 3 |
| Hu, M | 1 |
| Huang, P | 1 |
| Su, Y | 1 |
| Zhou, L | 1 |
| Zhu, X | 1 |
| Yan, D | 1 |
| Li, X | 1 |
| Shi, L | 1 |
| Wu, J | 1 |
| Ji, M | 1 |
| Zhao, J | 2 |
| Qiang, W | 1 |
| Ding, W | 1 |
| Jiang, J | 1 |
| Lu, Q | 1 |
| Wu, C | 1 |
| Fong, YC | 1 |
| Shuai, Y | 1 |
| Clifford, AK | 1 |
| Perkins, S | 1 |
| Steve, J | 1 |
| Choudry, MH | 1 |
| Gluskin, JS | 1 |
| Aguiló, A | 1 |
| Martínez C, J | 1 |
| Jarufe C, N | 1 |
| González D, R | 1 |
| Alvarez Z, M | 1 |
| Power, DG | 2 |
| Healey-Bird, BR | 1 |
| Sakai, T | 1 |
| Yamashita, Y | 1 |
| Maekawa, T | 1 |
| Mikami, K | 1 |
| Hoshino, S | 1 |
| Shirakusa, T | 1 |
| Khan, AZ | 1 |
| Morris-Stiff, G | 1 |
| Makuuchi, M | 1 |
| Hirata, K | 1 |
| Nakahara, S | 1 |
| Shimokobe, T | 1 |
| Imamura, T | 1 |
| Sakamoto, Y | 1 |
| Hirano, T | 1 |
| Abe, R | 1 |
| Kuroki, N | 1 |
| Konomi, K | 1 |
| Kato, H | 1 |
| Fujiwara, H | 1 |
| Fukuyama, N | 1 |
| Hotokezaka, M | 1 |
| Miyazaki, Y | 1 |
| Terasaka, R | 1 |
| Shiraishi, M | 1 |
| Miyazaki, R | 1 |
| Iwashita, A | 1 |
| Nakano, S | 1 |
| Ito, H | 2 |
| Jarnagin, W | 2 |
| Haviland, D | 1 |
| Dematteo, R | 1 |
| Melendez, FD | 1 |
| Schwartz, LH | 2 |
| Mocellin, S | 2 |
| Pasquali, S | 1 |
| Nitti, D | 3 |
| Townsend, A | 1 |
| Karapetis, C | 1 |
| Pilati, P | 1 |
| Mammano, E | 1 |
| Tessari, E | 1 |
| Lise, M | 2 |
| Alberts, SR | 2 |
| Roh, MS | 1 |
| Mahoney, MR | 2 |
| O'Connell, MJ | 6 |
| Nagorney, DM | 4 |
| Wagman, L | 1 |
| Smyrk, TC | 1 |
| Weiland, TL | 1 |
| Lai, LL | 1 |
| Schwarz, RE | 1 |
| Molina, R | 1 |
| Dentchev, T | 1 |
| Bolton, JS | 3 |
| Chen, Y | 2 |
| Yan, Z | 2 |
| Wang, J | 2 |
| Wang, X | 3 |
| Luo, J | 2 |
| Honda, T | 1 |
| Inagawa, H | 1 |
| Nishizawa, T | 1 |
| Yoshimura, H | 1 |
| Yamamoto, I | 1 |
| Soma, G | 1 |
| Kang, BW | 1 |
| Kim, JG | 2 |
| Lee, SJ | 1 |
| Chae, YS | 1 |
| Moon, JH | 1 |
| Sohn, SK | 1 |
| Jeon, SW | 1 |
| Jung, MK | 1 |
| Jang, YS | 1 |
| Park, JS | 1 |
| Jun, SH | 1 |
| Choi, GS | 1 |
| Samaras, P | 1 |
| Breitenstein, S | 1 |
| Haile, SR | 1 |
| Stenner-Liewen, F | 1 |
| Heinrich, S | 3 |
| Feilchenfeldt, J | 1 |
| Renner, C | 1 |
| Knuth, A | 1 |
| Pestalozzi, BC | 2 |
| Clavien, PA | 5 |
| Watanabe, T | 2 |
| Matsuda, K | 2 |
| Ishihara, S | 1 |
| Nozawa, K | 2 |
| Hayama, T | 2 |
| Yamada, H | 3 |
| Iinuma, H | 1 |
| Farr, GH | 1 |
| Fitch, TR | 1 |
| Maples, WJ | 1 |
| Rubin, J | 2 |
| Fuloria, J | 1 |
| Steen, PD | 1 |
| House, MG | 1 |
| Blumgart, LH | 3 |
| Ito, K | 1 |
| Bellot, GL | 1 |
| Tan, WH | 1 |
| Tay, LL | 1 |
| Koh, D | 1 |
| Patel, K | 1 |
| Yerram, SR | 1 |
| Azad, NA | 1 |
| Kern, SE | 2 |
| Mori, T | 2 |
| Ohue, M | 2 |
| Takii, Y | 1 |
| Hashizume, T | 1 |
| Kato, T | 3 |
| Kotake, K | 1 |
| Sato, T | 1 |
| Tango, T | 1 |
| Di Stefano, G | 1 |
| Busi, C | 1 |
| Fiume, L | 1 |
| Cheng, J | 1 |
| Glasgow, RE | 1 |
| O'Rourke, RW | 1 |
| Swanstrom, LL | 1 |
| Hansen, PD | 1 |
| Bilchik, AJ | 3 |
| Wood, TF | 2 |
| Chawla, SP | 2 |
| Rose, DM | 1 |
| Chung, MH | 1 |
| Stern, SS | 1 |
| Foshag, LJ | 2 |
| Ramming, KP | 2 |
| Barnett, KT | 1 |
| Malafa, MP | 1 |
| Petrowsky, H | 2 |
| Schwinnen, I | 1 |
| Staib-Sebler, E | 3 |
| Gog, C | 3 |
| El-Ganainy, A | 1 |
| Gutt, C | 1 |
| Müller, HH | 4 |
| Lorenz, M | 12 |
| Bonetti, A | 1 |
| Janciauskiene, R | 1 |
| Juozaityte, E | 1 |
| Pavalkis, D | 1 |
| Ahn, JH | 1 |
| Kim, TW | 1 |
| Lee, JH | 1 |
| Min, YJ | 1 |
| Kim, JC | 1 |
| Yu, CS | 1 |
| Kim, WK | 1 |
| Kang, YK | 1 |
| Lee, JS | 1 |
| Yanagisawa, M | 2 |
| Ishikawa, T | 1 |
| Ouchi, KF | 1 |
| Tanaka, Y | 4 |
| Gieschke, R | 1 |
| Burger, HU | 1 |
| Reigner, B | 1 |
| Blesch, KS | 1 |
| Steimer, JL | 1 |
| Brooks, A | 1 |
| Clingan, P | 1 |
| Morris, D | 1 |
| Dahm, F | 1 |
| Selzner, N | 3 |
| Selzner, M | 4 |
| Koda, K | 2 |
| Miyazaki, M | 2 |
| Sarashina, H | 1 |
| Suwa, T | 1 |
| Saito, N | 1 |
| Suzuki, M | 2 |
| Ogawa, K | 1 |
| Watanabe, S | 1 |
| Kodaira, S | 1 |
| Nakazato, H | 2 |
| Onaitis, M | 1 |
| Morse, M | 2 |
| Hurwitz, H | 1 |
| Cotton, P | 1 |
| Tyler, D | 1 |
| Clavien, P | 1 |
| Clary, B | 1 |
| Kapoor, V | 1 |
| Brancatelli, G | 1 |
| Federle, MP | 1 |
| Katyal, S | 1 |
| Marsh, JW | 1 |
| Stockman, J | 2 |
| Blumgart, L | 1 |
| Sperber, D | 1 |
| Hummer, A | 1 |
| Alimonti, A | 1 |
| Ferretti, G | 1 |
| Di Cosimo, S | 1 |
| Cognetti, F | 1 |
| Vecchione, A | 1 |
| Gill, S | 1 |
| Thomas, RR | 1 |
| Goldberg, RM | 2 |
| Sadahiro, S | 2 |
| Suzuki, T | 1 |
| Ishikawa, K | 1 |
| Masuda, T | 1 |
| Nakamura, T | 1 |
| Yasuda, S | 1 |
| Makuuchi, H | 1 |
| Murayama, C | 1 |
| Nishimura, G | 1 |
| Miwa, K | 1 |
| van Laarhoven, HW | 1 |
| Klomp, DW | 1 |
| Kamm, YJ | 1 |
| Punt, CJ | 1 |
| Heerschap, A | 1 |
| Ma, T | 1 |
| Zhu, ZG | 1 |
| Ji, YB | 1 |
| Zhang, Y | 1 |
| Yu, YY | 1 |
| Liu, BY | 1 |
| Yin, HR | 1 |
| Lin, YZ | 1 |
| Libra, M | 1 |
| Navolanic, PM | 1 |
| Talamini, R | 1 |
| Cecchin, E | 1 |
| Sartor, F | 1 |
| Tumolo, S | 1 |
| Masier, S | 1 |
| Travali, S | 1 |
| Boiocchi, M | 1 |
| Toffoli, G | 1 |
| Elias, D | 2 |
| de Baere, T | 1 |
| Sideris, L | 1 |
| Ducreux, M | 2 |
| Zhang, JM | 1 |
| Liu, MJ | 1 |
| Mizoi, T | 1 |
| Shiiba, K | 1 |
| Sasak, I | 1 |
| Matsuno, S | 1 |
| Mimori, K | 1 |
| Ueo, H | 1 |
| Kuroki, T | 1 |
| Shiraishi, T | 1 |
| Creer, S | 1 |
| Taylor, S | 1 |
| Ishii, H | 1 |
| Mori, M | 1 |
| Whisenant, J | 1 |
| Venook, A | 1 |
| Barber, FD | 1 |
| Mavligit, G | 1 |
| Kurzrock, R | 1 |
| Saiko, P | 1 |
| Horvath, Z | 1 |
| Bauer, W | 1 |
| Hoechtl, T | 1 |
| Grusch, M | 1 |
| Krupitza, G | 1 |
| Rauko, P | 1 |
| Mader, RM | 1 |
| Jaeger, W | 1 |
| Schott, H | 1 |
| Novotny, L | 1 |
| Fritzer-Szekeres, M | 1 |
| Szekeres, T | 1 |
| Oberfield, RA | 1 |
| Sampson, E | 1 |
| Heatley, GJ | 1 |
| Inoue, Y | 2 |
| Shirane, M | 1 |
| Miki, C | 1 |
| Hiro, J | 1 |
| Tanaka, K | 1 |
| Kobayashi, M | 1 |
| Mori, K | 1 |
| Yanagi, H | 1 |
| Kusunoki, M | 1 |
| Hasegawa, S | 1 |
| Seike, K | 1 |
| Takiguchi, N | 1 |
| Oda, K | 1 |
| Hasegawa, R | 1 |
| Mishima, H | 2 |
| Tsujinaka, T | 1 |
| Nishisho, I | 1 |
| Tsujie, M | 2 |
| Fujimoto-Ouchi, K | 1 |
| Kikkawa, N | 1 |
| Fiorentini, G | 1 |
| Rossi, S | 1 |
| Bernardeschi, P | 1 |
| Cantore, M | 1 |
| Guadagni, S | 1 |
| Ensminger, WD | 5 |
| Phongkitkarun, S | 1 |
| Kobayashi, S | 1 |
| Varavithya, V | 1 |
| Huang, X | 1 |
| Curley, SA | 3 |
| Charnsangavej, C | 1 |
| Sawada, T | 1 |
| Nishimura, M | 1 |
| Hirose, K | 1 |
| Ogata, Y | 2 |
| Matono, K | 2 |
| Sasatomi, T | 1 |
| Ishibashi, N | 2 |
| Ohkita, A | 1 |
| Mizobe, T | 2 |
| Ogo, S | 1 |
| Ikeda, S | 3 |
| Ozasa, H | 2 |
| Shirouzu, K | 2 |
| Guichard, SM | 1 |
| Mayer, I | 1 |
| Jodrell, DI | 1 |
| Schmitz, R | 2 |
| Krakamp, B | 2 |
| Troidl, H | 1 |
| Ben-Josef, E | 1 |
| Normolle, D | 2 |
| Walker, S | 3 |
| Tatro, D | 1 |
| Ten Haken, RK | 2 |
| Knol, J | 1 |
| Dawson, LA | 2 |
| Pan, C | 1 |
| Lawrence, TS | 5 |
| Kerr, C | 1 |
| Homsi, J | 1 |
| Garrett, CR | 1 |
| Kadry, Z | 1 |
| Wildermuth, S | 1 |
| Mori, S | 1 |
| Akagi, Y | 1 |
| Murakami, H | 1 |
| Brody, JR | 1 |
| Hucl, T | 1 |
| Gallmeier, E | 1 |
| Winter, JM | 1 |
| Murphy, KM | 1 |
| Ryan, DP | 1 |
| Oomi, T | 1 |
| Nakamura, K | 1 |
| Aoyagi, Y | 1 |
| Haku, K | 1 |
| Mimura, T | 1 |
| Ikenaga, M | 1 |
| Murata, K | 2 |
| Fukunaga, M | 1 |
| Ota, H | 1 |
| Tominaga, S | 1 |
| Ohnishi, T | 2 |
| Amano, M | 3 |
| Ikeda, K | 2 |
| Ikeda, M | 1 |
| Sekimoto, M | 2 |
| Sakamoto, J | 1 |
| Monden, M | 3 |
| Nishioka, M | 1 |
| Miyamoto, H | 1 |
| Kurita, N | 1 |
| Higashijima, J | 1 |
| Yoshikawa, K | 1 |
| Miyatani, T | 1 |
| Shimada, M | 1 |
| Ardalan, B | 1 |
| Kozyreva, O | 1 |
| Tsai, KT | 1 |
| Santos, E | 1 |
| Franceschi, D | 1 |
| Livingstone, A | 1 |
| Lima, M | 1 |
| Yezhelyev, M | 1 |
| Osgood, M | 1 |
| Egnatashvili, V | 1 |
| Lumsden, A | 1 |
| Staley, CA | 1 |
| Kooby, DA | 1 |
| Pulitanò, C | 1 |
| Arru, M | 1 |
| Catena, M | 1 |
| Guzzetti, E | 1 |
| Vitali, G | 1 |
| Ronzoni, M | 1 |
| Venturini, M | 1 |
| Villa, E | 1 |
| Ferla, G | 1 |
| Aldrighetti, L | 1 |
| White, RR | 1 |
| Munoz, JA | 1 |
| Raggio, G | 1 |
| Rossion, I | 2 |
| Koch, B | 1 |
| Encke, A | 4 |
| Leichman, CG | 1 |
| Allen-Mersh, TG | 11 |
| Earlam, S | 4 |
| Fordy, C | 7 |
| Abrams, K | 1 |
| Houghton, J | 1 |
| Burke, D | 3 |
| Twort, P | 1 |
| Rubin, JT | 1 |
| Lotze, MT | 1 |
| Rosenfelder, D | 1 |
| Brumfield, A | 1 |
| Howells, R | 1 |
| Schwartz, R | 1 |
| Sylvestri, S | 1 |
| Sammon, J | 1 |
| Bron, K | 1 |
| Orens, P | 1 |
| Bajetta, E | 5 |
| Colleoni, M | 3 |
| Di Bartolomeo, M | 3 |
| Buzzoni, R | 2 |
| Bozzetti, F | 1 |
| Doci, R | 1 |
| Somma, L | 3 |
| Cappuzzo, F | 1 |
| Stampino, CG | 2 |
| Guenzi, A | 1 |
| Lévi, F | 3 |
| Spagliardi, E | 1 |
| Torelli, P | 1 |
| Barra, M | 1 |
| Orsi, D | 1 |
| Bruzzo, F | 1 |
| Robertson, JM | 1 |
| Kessler, ML | 1 |
| Andrews, JC | 1 |
| McCall, JL | 1 |
| Jorgensen, JO | 1 |
| Morris, DL | 2 |
| Falcone, A | 2 |
| Pfanner, E | 2 |
| Cianci, C | 2 |
| Danesi, R | 1 |
| Brunetti, I | 1 |
| Del Tacca, M | 1 |
| Conte, PF | 1 |
| Ng, B | 2 |
| Lenert, JT | 2 |
| Weksler, B | 1 |
| Port, JL | 2 |
| Ellis, JL | 2 |
| Burt, ME | 2 |
| Ricci, S | 1 |
| Bertuccelli, M | 1 |
| Carrai, M | 1 |
| De Marco, S | 1 |
| Ceribelli, A | 1 |
| Barduagni, M | 1 |
| Calabresi, F | 3 |
| Inaba, M | 2 |
| Mitsuhashi, J | 2 |
| Takahashi, K | 1 |
| Kameyama, M | 3 |
| Nakamori, S | 2 |
| Imaoka, S | 3 |
| Yasuda, T | 3 |
| Nakano, H | 2 |
| Ohigashi, H | 3 |
| Hiratsuka, M | 3 |
| Kabuto, T | 3 |
| Ishikawa, O | 3 |
| Haruta, A | 1 |
| Umeno, T | 1 |
| Tanaka, S | 1 |
| Toriya, H | 1 |
| Jyozaki, H | 1 |
| Conti, JA | 5 |
| Cohen, A | 6 |
| Campana, P | 1 |
| Huang, Y | 2 |
| Shi, WJ | 1 |
| Botet, J | 6 |
| Pulliam, S | 1 |
| Bertino, JR | 6 |
| Arisawa, Y | 2 |
| Sutanto-Ward, E | 3 |
| Dalton, RR | 1 |
| Sigurdson, ER | 7 |
| Begos, DG | 1 |
| Ballantyne, GH | 1 |
| Castoldi, MC | 1 |
| Dellafiore, L | 1 |
| Pancera, G | 1 |
| Yamaguchi, A | 1 |
| Maeda, A | 1 |
| Hachisuka, K | 1 |
| Yura, J | 1 |
| Honda, K | 1 |
| Honda, H | 1 |
| Yoshizaki, S | 1 |
| Tsuruga, N | 1 |
| Hughey, CT | 1 |
| Barbour, KW | 2 |
| Berger, FG | 2 |
| Berger, SH | 3 |
| Levin, RD | 1 |
| Gordon, JH | 1 |
| Canman, CE | 1 |
| Shewach, DS | 1 |
| Tang, HY | 1 |
| Maybaum, J | 3 |
| de Takats, PG | 1 |
| Kerr, DJ | 1 |
| Poole, CJ | 1 |
| Warren, HW | 1 |
| McArdle, CS | 1 |
| Watanabe, K | 1 |
| Igarashi, T | 1 |
| Hayashi, T | 1 |
| Yoshida, K | 1 |
| Hanyu, F | 1 |
| Seiter, K | 4 |
| Chapman, D | 5 |
| Mazumdar, M | 1 |
| Budd, AJ | 1 |
| Hottenrott, C | 4 |
| Campbell, KA | 1 |
| Burns, RC | 1 |
| Sitzmann, JV | 1 |
| Lipsett, PA | 1 |
| Grochow, LB | 1 |
| Niederhuber, JE | 1 |
| Rosso, R | 1 |
| Sobrero, A | 1 |
| Amadori, D | 1 |
| Comella, G | 2 |
| Marangolo, M | 1 |
| Scanni, A | 2 |
| Lorusso, V | 1 |
| Lokich, JJ | 1 |
| Anderson, N | 1 |
| Ahlgren, JD | 1 |
| Tao, Y | 1 |
| Niedzwiecki, D | 6 |
| Budd, A | 1 |
| Campos, LT | 1 |
| Sigurdson, E | 2 |
| Lincer, R | 2 |
| Costa, P | 1 |
| Patt, YZ | 1 |
| Davis, ST | 2 |
| Garufi, C | 1 |
| Giunta, S | 1 |
| Aschelter, A | 1 |
| Pace, R | 1 |
| Nisticò, C | 1 |
| Terzoli, E | 1 |
| Hanisch, E | 1 |
| Piedbois, P | 4 |
| Buyse, M | 4 |
| Rougier, P | 4 |
| Carlson, R | 2 |
| Allen-Mersh, T | 1 |
| O'Connell, M | 1 |
| Chang, A | 1 |
| Sondak, V | 1 |
| Kemeny, M | 1 |
| Levy, E | 1 |
| Doroshow, JH | 1 |
| Cao, S | 1 |
| Frank, C | 1 |
| Rustum, YM | 3 |
| Anand, A | 2 |
| Anand, N | 1 |
| Tremiterra, S | 2 |
| Nawata, S | 1 |
| Harmantas, A | 1 |
| Rotstein, LE | 1 |
| Langer, B | 1 |
| Davidson, BS | 1 |
| Izzo, F | 1 |
| Chase, JL | 2 |
| DuBrow, RA | 1 |
| Patt, Y | 1 |
| Hohn, DC | 3 |
| Iwagaki, H | 1 |
| Hizuta, A | 1 |
| Fujiwara, T | 1 |
| Perdomo, JA | 1 |
| Tanaka, N | 2 |
| Orita, K | 1 |
| Moreschi, M | 1 |
| Turci, D | 1 |
| Gebbia, V | 1 |
| Bordogna, G | 1 |
| Ruffin, WK | 1 |
| Furukawa, H | 2 |
| Iwanaga, T | 1 |
| Yokouchi, H | 1 |
| Doi, O | 1 |
| Takeda, A | 1 |
| Shimada, H | 2 |
| Ariga, T | 1 |
| Ohshima, I | 1 |
| Maruyama, T | 1 |
| Kinoshita, H | 1 |
| Yoshimura, S | 1 |
| Shoko, T | 1 |
| Maeda, T | 1 |
| Ozaki, M | 1 |
| Glover, C | 3 |
| Davies, M | 1 |
| Durand-Zaleski, I | 1 |
| Roche, B | 1 |
| Chang, AE | 1 |
| Sondak, VK | 1 |
| Kemeny, MM | 3 |
| Fagniez, PL | 1 |
| Le Bourgeois, JP | 1 |
| Tomoda, H | 1 |
| Morita, M | 1 |
| Matsuoka, H | 1 |
| Baba, H | 2 |
| Taketomi, A | 1 |
| Kohnoe, S | 1 |
| Seo, Y | 1 |
| Saito, T | 1 |
| Del Vecchio, M | 1 |
| Artale, S | 1 |
| Zunino, F | 1 |
| Bignami, P | 2 |
| Magnani, E | 1 |
| Isacoff, WH | 1 |
| Borud, K | 1 |
| Kornmann, M | 3 |
| Link, KH | 3 |
| Pillasch, J | 2 |
| Metzger, R | 1 |
| Butzer, U | 1 |
| Leder, GH | 2 |
| Weindel, M | 1 |
| Safi, F | 8 |
| Danenberg, KD | 1 |
| Beger, HG | 5 |
| Danenberg, PV | 2 |
| Civalleri, D | 4 |
| De Cian, F | 1 |
| Pellicci, R | 1 |
| Balletto, N | 4 |
| Simoni, G | 1 |
| Cosimelli, M | 2 |
| Mondini, G | 1 |
| Cagol, PP | 1 |
| Davies, MM | 3 |
| van Laar, JA | 1 |
| Ackland, SP | 1 |
| van Groeningen, CJ | 2 |
| Peters, GJ | 1 |
| Naoe, Y | 1 |
| Bernath, AM | 1 |
| Schroeder, G | 1 |
| Fitzgibbons, RJ | 2 |
| Mailliard, JA | 2 |
| Burch, P | 1 |
| Colon-Otero, G | 1 |
| Krook, JE | 2 |
| Tsugawa, T | 1 |
| Monden, T | 3 |
| Haba, A | 2 |
| Kanoh, T | 1 |
| Izawa, H | 1 |
| Sekimoro, M | 1 |
| Tomita, N | 2 |
| Okamura, J | 1 |
| Hosoya, Y | 1 |
| Konishi, H | 1 |
| Horie, H | 1 |
| Ishizuka, T | 1 |
| Shitou, K | 1 |
| Kojima, M | 1 |
| Kashiwagi, H | 1 |
| Kanazawa, K | 1 |
| Yamane, E | 1 |
| Nanri, M | 1 |
| Chimori, Y | 1 |
| Oguro, A | 1 |
| Fujita, Y | 1 |
| Ikoma, H | 1 |
| Neri, B | 1 |
| Gemelli, MT | 1 |
| Pantalone, D | 1 |
| Pernice, ML | 1 |
| Agostino, I | 1 |
| Scatizzi, M | 1 |
| Siliani, GM | 1 |
| Bartolini, P | 1 |
| Andreoli, F | 1 |
| Gassel, HJ | 1 |
| Mattes, P | 1 |
| Stieger, R | 1 |
| Schramm, H | 1 |
| Johnston, PG | 1 |
| Kaur, S | 1 |
| Leder, G | 1 |
| Pillasch, AF | 1 |
| Sunelaitis, E | 1 |
| Schatz, M | 1 |
| Pressmar, J | 1 |
| Berlin, J | 1 |
| Merrick, HW | 1 |
| Smith, TJ | 1 |
| Lerner, H | 1 |
| Focan, C | 2 |
| Kreutz, F | 1 |
| Focan-Henrard, D | 2 |
| Lobelle, JP | 1 |
| Adam, R | 1 |
| Dallemagne, B | 2 |
| Jehaes, C | 2 |
| Markiewicz, S | 2 |
| Weerts, J | 2 |
| Bismuth, H | 1 |
| Jasmin, C | 1 |
| Misset, JL | 1 |
| Honda, M | 1 |
| Matsuo, Y | 1 |
| Yamamoto, S | 1 |
| Hazama, K | 1 |
| Takao, T | 1 |
| Fushimi, H | 1 |
| Evrard, A | 1 |
| Cuq, P | 1 |
| Ciccolini, J | 1 |
| Vian, L | 1 |
| Cano, JP | 1 |
| Morse, MA | 1 |
| Cohen, AM | 1 |
| Shi, W | 1 |
| Brennan, MF | 1 |
| Turnbull, AD | 1 |
| Sullivan, D | 1 |
| Thirion, P | 2 |
| Wolmark, N | 1 |
| Haddad, E | 1 |
| Vetter, G | 1 |
| Sakita, I | 1 |
| Tamaki, Y | 1 |
| Atkins, CD | 1 |
| Venook, AP | 3 |
| Althaus, B | 1 |
| Warren, RS | 3 |
| Hochmuth, K | 1 |
| McGinn, CJ | 1 |
| Ensminger, W | 1 |
| Fata, F | 1 |
| Ron, IG | 1 |
| Maluf, F | 1 |
| Klimstra, D | 1 |
| Murakami, Y | 1 |
| Kazuno, H | 1 |
| Emura, T | 1 |
| Tsujimoto, H | 1 |
| Suzuki, N | 1 |
| Fukushima, M | 1 |
| van Riel, JM | 1 |
| Giaccone, G | 1 |
| Pinedo, HM | 1 |
| Carlson, RW | 1 |
| Burzykowski, T | 1 |
| Molenberghs, G | 1 |
| Tono, T | 1 |
| Mathur, P | 1 |
| Quinn, H | 1 |
| Croockewit, A | 1 |
| Schellens, J | 1 |
| van Bronswijk, H | 1 |
| Lekkerkerker, JF | 1 |
| Koopmans, PP | 1 |
| Ribaudo, HJ | 1 |
| Thompson, SG | 1 |
| Arai, Y | 2 |
| Matsueda, K | 2 |
| Inaba, Y | 2 |
| Libutti, SK | 1 |
| Figg, WD | 1 |
| Fraker, DL | 1 |
| Alexander, HR | 1 |
| Maruyama, M | 1 |
| Toukairin, Y | 1 |
| Yoshida, T | 1 |
| Kure, N | 1 |
| Nagahama, T | 1 |
| Ebuchi, M | 1 |
| Porta, C | 1 |
| Danova, M | 1 |
| Accurso, S | 1 |
| Tinelli, C | 1 |
| Girino, M | 1 |
| Riccardi, A | 1 |
| Palmeri, S | 1 |
| Tanaka-Nozaki, M | 1 |
| Onda, M | 1 |
| Kato, S | 1 |
| Ike, H | 1 |
| Oya, K | 1 |
| Otani, Y | 1 |
| Yamaguchi, S | 1 |
| Hiki, Y | 1 |
| Fujita, H | 1 |
| Mitomi, T | 1 |
| Fujioka, M | 1 |
| Ohsawa, T | 1 |
| Takeuchi, I | 1 |
| Nakada, H | 1 |
| Ishizuka, N | 1 |
| Yokoyama, M | 1 |
| Inokuma, S | 1 |
| Odaka, A | 1 |
| Hoshino, T | 1 |
| Murata, N | 1 |
| Hashimoto, D | 1 |
| Matsumoto, Y | 1 |
| Miura, T | 1 |
| Khan, ZA | 1 |
| Jonas, SK | 1 |
| Feldmann, KA | 1 |
| Patel, H | 1 |
| Wharton, RQ | 1 |
| Tarragona, A | 1 |
| Ivison, A | 1 |
| Gray, B | 2 |
| Van Hazel, G | 1 |
| Hope, M | 1 |
| Burton, M | 1 |
| Moroz, P | 1 |
| Anderson, J | 1 |
| Gebski, V | 1 |
| Aramaki, T | 1 |
| Wagman, LD | 2 |
| Litvak, DA | 1 |
| Tsioulias, GJ | 1 |
| Chung, M | 1 |
| Morton, DL | 1 |
| Adak, S | 1 |
| Macdonald, JS | 1 |
| Smith, T | 1 |
| Lipsitz, S | 1 |
| O'Dwyer, PJ | 1 |
| Benson, AB | 1 |
| Gruenberger, T | 1 |
| King, J | 1 |
| Chung, T | 1 |
| Clingan, PR | 1 |
| Paulson, E | 1 |
| Dizon, DS | 1 |
| Aschele, C | 1 |
| Lonardi, S | 1 |
| Monfardini, S | 1 |
| Laplanche, A | 1 |
| Huguier, M | 1 |
| Hay, JM | 1 |
| Ollivier, JM | 1 |
| Escat, J | 1 |
| Salmon, R | 1 |
| Julien, M | 1 |
| Roullet Audy, JC | 1 |
| Gallot, D | 1 |
| Oderman, P | 4 |
| Murray, P | 1 |
| Sugimoto, Y | 1 |
| Ohe, Y | 1 |
| Nishio, K | 1 |
| Ohmori, T | 1 |
| Fujiwara, Y | 1 |
| Saijo, N | 1 |
| Moertel, CG | 1 |
| Pfeifer, T | 1 |
| Häussler, MD | 1 |
| Tomczak, R | 1 |
| Rilinger, N | 1 |
| Zeitler, H | 1 |
| Laasch, HU | 1 |
| Friedrich, JM | 2 |
| de Braud, F | 1 |
| Zilembo, N | 1 |
| Nolè, F | 1 |
| Nelli, P | 1 |
| Marsh, JC | 1 |
| Durivage, HJ | 1 |
| Davis, C | 1 |
| O'Hollaren, K | 1 |
| Pasquale, DN | 1 |
| Simonich, SA | 1 |
| Voynick, IM | 1 |
| Maier, P | 1 |
| Reimann, M | 1 |
| Inglis, R | 2 |
| Tevaearai, HT | 1 |
| Laurent, PL | 1 |
| Suardet, L | 1 |
| Eliason, JF | 1 |
| Givel, JC | 1 |
| Odartchenko, N | 1 |
| Cavallini, M | 2 |
| Cortesi, E | 1 |
| Decian, F | 2 |
| Arnone, GB | 1 |
| Tirindelli Danesi, D | 1 |
| Depaoli, M | 1 |
| Stagg, RJ | 2 |
| Lewis, BJ | 2 |
| Roh, M | 1 |
| Mulvihill, SJ | 1 |
| Grobman, BJ | 1 |
| Rayner, AA | 1 |
| Dusenbury, CE | 2 |
| Davis, MA | 1 |
| Burton, EC | 1 |
| Shelton, DA | 1 |
| Jing, HW | 1 |
| Stetson, PL | 1 |
| Repetto, M | 1 |
| Machover, D | 1 |
| Mannella, E | 1 |
| Anzá, M | 1 |
| Di Tora, P | 1 |
| Durante, F | 1 |
| Porcellana, M | 1 |
| Cavaliere, P | 1 |
| Anfossi, A | 1 |
| Da Pian, PP | 1 |
| Pilati, PL | 1 |
| Scheele, J | 1 |
| Stangl, R | 1 |
| Altendorf-Hofmann, A | 1 |
| Gall, FP | 1 |
| Mazy, V | 1 |
| Longrée, L | 1 |
| Jacquet, N | 1 |
| Demoulin, JC | 1 |
| Sakatoku, M | 1 |
| Kikkawa, H | 1 |
| Hirano, M | 1 |
| Matsu, T | 1 |
| Harada, T | 1 |
| Saito, H | 1 |
| Tatsuzawa, T | 1 |
| Masuda, S | 1 |
| Martin, JK | 1 |
| Wieand, HS | 1 |
| Tschetter, LK | 1 |
| Schumacher, K | 1 |
| Roscher, R | 3 |
| Bittner, R | 2 |
| Hrushesky, WJ | 1 |
| Leong, L | 1 |
| Terz, JJ | 1 |
| Hill, LR | 1 |
| Beatty, JD | 1 |
| Kokal, WA | 1 |
| Riihimaki, DU | 1 |
| Tuchmann, A | 1 |
| Schüller, J | 1 |
| Kroiss, A | 1 |
| Dinstl, K | 1 |
| Herrmann, R | 1 |
| Shurgot, B | 1 |
| Roth, J | 2 |
| Schumacher, KA | 3 |
| Williams, NN | 1 |
| Daly, JM | 1 |
| Schuhmacher, K | 1 |
| Gaus, W | 2 |
| Beger, GH | 1 |
| Mennigen, R | 1 |
| Barkun, J | 1 |
| Klauke, H | 1 |
| Lasser, P | 1 |
| Ghosn, M | 1 |
| Lumbroso, J | 1 |
| Sidibe, S | 1 |
| Droz, JP | 1 |
| Bitter, R | 1 |
| Schneider, A | 1 |
| Angelini, F | 1 |
| Coppetelli, U | 1 |
| Carassai, A | 1 |
| Lopez, M | 1 |
| Friedman, MA | 1 |
| Hannigan, JF | 1 |
| Rayner, A | 1 |
| Ignoffo, RJ | 1 |
| Acord, P | 1 |
| Didolkar, MS | 1 |
| Kirkowa-Reimann, M | 1 |
| Buzaid, AC | 1 |
| Alberts, DS | 1 |
| Einspahr, J | 1 |
| Mosley, K | 1 |
| Peng, YM | 1 |
| Tutsch, K | 1 |
| Spears, CP | 1 |
| Garewal, HS | 1 |
| Planting, AS | 1 |
| Runhaar, EA | 1 |
| Verwey, J | 1 |
| Taal, BG | 1 |
| Blijham, G | 1 |
| Neyt, JP | 1 |
| Seeger, J | 1 |
| Woodcock, TM | 1 |
| Blumenreich, MS | 1 |
| Richardson, JD | 1 |
| Weidenmaier, WE | 1 |
| Park, JG | 1 |
| Collins, JM | 1 |
| Gazdar, AF | 1 |
| Allegra, CJ | 1 |
| Steinberg, SM | 1 |
| Greene, RF | 1 |
| Kramer, BS | 1 |
| Ficorella, C | 1 |
| Cagnazzo, P | 1 |
| Cardi, G | 1 |
| Ricciuti, FP | 1 |
| Marchetti, P | 1 |
| Frati, L | 1 |
| Marchei, P | 1 |
| Glimelius, B | 1 |
| Påhlman, L | 1 |
| Schaaf, LJ | 1 |
| Dobbs, BR | 1 |
| Edwards, IR | 1 |
| Perrier, DG | 1 |
| Muhrer, KH | 1 |
| Schwemmle, K | 1 |
| Nishiyama, M | 1 |
| Takagami, S | 1 |
| Kirihara, Y | 1 |
| Saeki, T | 1 |
| Hirabayashi, N | 1 |
| Nosoh, Y | 1 |
| Niimoto, M | 1 |
| Hattori, T | 1 |
| Taylor, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Phase II Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer[NCT01312857] | Phase 2 | 75 participants (Actual) | Interventional | 2011-03-31 | Active, not recruiting | ||
| A Single-Arm Phase II Study of Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver[NCT03366155] | Phase 2 | 40 participants (Anticipated) | Interventional | 2019-06-24 | Recruiting | ||
| A Phase II Study of the Rate of Conversion to Complete Resection in Patients With Initially Inoperable Hepatic-Only Metastases From Colorectal Cancer After Treatment With Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Bes[NCT00492999] | Phase 2 | 64 participants (Anticipated) | Interventional | 2007-05-31 | Active, not recruiting | ||
| A Phase I Study Of Hepatic Arterial Infusion With Floxuridine And Dexamethasone In Combination With Intravenous Oxaliplatin Plus 5-Fluorouracil And Leucovorin In Patients With Unresectable Hepatic Metastases From Colorectal Cancer[NCT00008294] | Phase 1 | 0 participants | Interventional | 2000-08-31 | Completed | ||
| Pilot Study of Hepatic Arterial Infusion Therapy in Patients With Unresectable or Borderline Resectable Intrahepatic Cholangiocarcinoma[NCT01525069] | Phase 1 | 27 participants (Actual) | Interventional | 2012-04-03 | Terminated (stopped due to Equipment that was used in the study was discontinued) | ||
| A Phase II Trial Evaluating Multiple Metastasectomy Combined With Hepatic Artery Infusion Of Floxuridine (FUDR) And Dexamethasone (DXM), Alternating With Systemic Oxaliplatin (OXAL) And Capecitabine (CAPCIT) For Colorectal Carcinoma Metastatic To The Live[NCT00026234] | Phase 2 | 75 participants (Actual) | Interventional | 2002-02-28 | Completed | ||
| A Phase 2 Study of Low-Dose Fractionated Radiation Therapy to the Whole Liver in Combination With Gemcitabine and Cisplatin in Locally Advanced Mass-Forming Intrahepatic Cholangiocarcinoma[NCT02254681] | Phase 2 | 6 participants (Actual) | Interventional | 2014-09-30 | Terminated (stopped due to lack of funding) | ||
| A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the Liver[NCT00001576] | Phase 1 | 28 participants | Interventional | 1997-07-31 | Completed | ||
| Short-term Effects of Laparoscopic-assisted Small-incision Surgery Versus Conventional Laparotomy in Treatment of Resectable Colorectal Liver Metastasis[NCT02350166] | Phase 3 | 40 participants (Anticipated) | Interventional | 2013-11-30 | Recruiting | ||
| A Phase III Randomized Trial of Standard Dose Stereotactic Body Radiation Therapy (SBRT) Versus Radiobiologically-Guided Dose Selected SBRT In Primary or Secondary Liver Carcinoma (SAVIOR).[NCT04745390] | 110 participants (Anticipated) | Interventional | 2021-08-01 | Recruiting | |||
| Human Liver Explants for HIF-1 Alpha- Analysis/Comparison[NCT00866957] | 180 participants (Actual) | Observational | 2006-02-28 | Completed | |||
| Phase II Trial of TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma[NCT04923529] | Phase 2 | 28 participants (Anticipated) | Interventional | 2021-03-01 | Recruiting | ||
| A Phase I Trial of Isolated Hepatic Perfusion With Oxaliplatin Followed by Hepatic Arterial Infusion of FUDR and Leucovorin for Patients With Unresectable Colorectal Liver Metastases[NCT01042691] | Phase 1 | 10 participants (Actual) | Interventional | 2003-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To determine the number of participants with Intrahepatic disease progression assessed by MRI of the abdomen with intravenous gadolinium contrast using RECIST criteria. (NCT02254681)
Timeframe: From date of first treatment until date of first documented progression or date of death from any cause, which ever comes first, assessed up to 24 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 6 |
To determine the number of participants with Intrahepatic recurrence assessed by RECIST criteria using MRI of the abdomen with intravenous gadolinium contrast. (NCT02254681)
Timeframe: From date of partial hepatectomy until date of first documented recurrence or date of death from any cause, assessed up to 24 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 1 |
Measured post-operative complications include (but not limited to) bile leak, liver failure, ascites, infection, any organ failure or insufficiency, venous thromboembolism, and mortality. (NCT02254681)
Timeframe: up to 90 days after partial hepatectomy
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 1 |
59 reviews available for floxuridine and Colorectal Cancer
| Article | Year |
|---|---|
Oral versus intravenous fluoropyrimidines for colorectal cancer.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Camptothecin; Capecitabine; Chemotherapy, Adjuva | 2017 |
Place of hepatic intra-arterial chemotherapy in the treatment of colorectal liver metastases.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, A | 2014 |
[Current therapeutic options for liver metastasis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Catheter Ablation; Colorect | 2008 |
Regional chemotherapy for liver-limited metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neo | 2008 |
Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modalit | 2009 |
Fluoropyrimidine-HAI (hepatic arterial infusion) versus systemic chemotherapy (SCT) for unresectable liver metastases from colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm | 2009 |
Selective internal radiation therapy for liver metastases from colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Floxuridine; Fluor | 2009 |
Chemotherapy for the conversion of unresectable colorectal cancer liver metastases to resection.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Therapy; Camptothecin; Chemotherapy, Adju | 2011 |
Complications of hepatic artery infusion: a review of 4580 reported cases.
Topics: Antimetabolites, Antineoplastic; Arterial Occlusive Diseases; Bone Marrow Diseases; Catheters, Indwe | 2001 |
[The role of the regional (intra-arterial) chemotherapy in the treatment of hepatic metastases of colorectal cancer].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2003 |
Arterial chemotherapy as adjuvant and palliative treatment of hepatic colorectal metastases: an update.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Flox | 2003 |
Review article: colorectal cancer chemotherapy.
Topics: Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Ne | 2003 |
[Doxifluridine for treatment of colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Floxuridine; Flu | 2003 |
Regional chemotherapeutic techniques for liver tumors: current knowledge and future directions.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Colorectal Neoplasms; Dose-Response Relationship, | 2004 |
Defining the role of hepatic arterial infusion chemotherapy in metastatic colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Floxuridine; Fluorour | 2004 |
Hepatic arterial infusion chemotherapy for metastatic colorectal cancer: a concise overview.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Flo | 2004 |
Nonsurgical approaches to colorectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Che | 2006 |
A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Comb | 2008 |
[Results of resection and adjuvant therapy of liver metastases of primary colorectal tumors--a review of the literature].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regiona | 1995 |
Prolonged infusion of fluorinated pyrimidines in gastrointestinal malignancies: a review of recent clinical trials.
Topics: Carcinoma, Squamous Cell; Circadian Rhythm; Cisplatin; Clinical Trials as Topic; Colorectal Neoplasm | 1994 |
[What is the value of arterial chemotherapy in treatment of colorectal liver metastases].
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Floxu | 1994 |
[Adjuvant and palliative regional therapy of liver metastases in colorectal tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Region | 1995 |
Update on regional treatments for hepatobiliary malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; | 1995 |
Hepatic artery chemotherapy for colorectal liver metastases.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infu | 1995 |
Hepatic arterial chemotherapy for metastatic colorectal carcinoma.
Topics: Colorectal Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; | 1994 |
Recent advances in the treatment of advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colorectal Neoplasms; Drug Administra | 1993 |
Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Floxuridine; Fluorouracil; Health Care Costs; | 1996 |
Biochemical modulation of fluoropyrimidines: is there an optimal (6R,S) leucovorin dose and schedule?
Topics: Animals; Antimetabolites, Antineoplastic; Colonic Neoplasms; Colorectal Neoplasms; Floxuridine; Fluo | 1996 |
Regional versus systemic chemotherapy in the treatment of colorectal carcinoma metastatic to the liver. Is there a survival difference? Meta-analysis of the published literature.
Topics: Colorectal Neoplasms; Floxuridine; Fluorouracil; Humans; Infusions, Intra-Arterial; Liver Neoplasms; | 1996 |
Hepatic arterial infusion for metastatic colorectal cancer: the price of "success".
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Hu | 1996 |
Economic implications of hepatic arterial infusion chemotherapy in treatment of nonresectable colorectal liver metastases. Meta-Analysis Group in Cancer.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Cost-Benefit Analysis; Decision Making; Drug | 1997 |
Chemotherapy for the treatment of patients with metastatic colorectal cancer: an overview.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Flox | 1997 |
Chemotherapy of colorectal cancer: history and new themes.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 1997 |
Comparison of 5-fluoro-2'-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Cell Division; Clinical Trials as Topic; Colorectal Neoplasms; Flox | 1998 |
[PyNPase expression and cancer progression in the colorectum].
Topics: Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Colorectal Neoplasms; Disease Progressi | 1998 |
Is repeated treatment with a 5-fluorouracil-based regimen useful in colorectal cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Floxuridine; Flu | 1998 |
Basic research supported developments of chemotherapy in nonresectable isolated colorectal liver metastases to a protocol of hepatic artery infusion using mitoxantrone, 5-FU + folinic acid and mitomycin C.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Drug | 1999 |
Survival impact of chemotherapy in patients with colorectal metastases confined to the liver: a re-analysis of 1458 non-operable patients randomised in 22 trials and 4 meta-analyses. Meta-Analysis Group in Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 1999 |
Relevance of locoregional chemotherapy in patients with liver metastases from colorectal primaries.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Floxuridine; Fluorouracil; Follow-Up Studies; | 2000 |
Hepatic arterial chemotherapy for colorectal cancer metastatic to the liver.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Hu | 2000 |
Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm | 2000 |
[The role of prophylactic hepatic arterial infusion chemotherapy after potentially curative resection of hepatic metastases from colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hepatectomy; Hepat | 2000 |
[Hepatic arterial infusion chemotherapy for liver metastases from colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fema | 2000 |
Therapeutic approaches to metastasis confined to the liver.
Topics: Antimetabolites, Antineoplastic; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Colorectal | 2001 |
[Evidence for and practical use of arterial infusion chemotherapy for liver metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; | 2002 |
Intrahepatic arterial infusion of chemotherapy: pharmacologic principles.
Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Fl | 2002 |
Intrahepatic arterial infusion of chemotherapy: clinical results.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Floxuridine; Fluor | 2002 |
Thymidylate Synthase expression as a predictor of clinical response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer.
Topics: Colorectal Neoplasms; Cytological Techniques; Drug Resistance, Neoplasm; Floxuridine; Fluorouracil; | 2002 |
Review of regional therapy of liver metastases in colorectal cancer.
Topics: Colorectal Neoplasms; Floxuridine; Hepatic Artery; Humans; Infusion Pumps; Infusions, Intra-Arterial | 1992 |
Is hepatic infusion of chemotherapy effective treatment for liver metastases? No!
Topics: Antineoplastic Agents; Colorectal Neoplasms; Floxuridine; Fluorouracil; Forecasting; Humans; Infusio | 1992 |
Modulation of fluoropyrimidines by leucovorin: rationale and status.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; | 1991 |
Doxifluridine in advanced colorectal cancer.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Drug Administration Schedule; Floxuridine; Humans; Isom | 1991 |
Developments of the fluoropyrimidines as inhibitors of thymidylate synthetase: pharmacologic and clinical aspects.
Topics: Animals; Antineoplastic Agents; Colorectal Neoplasms; Drug Synergism; Floxuridine; Fluorouracil; Hum | 1991 |
[Intra-arterial and intravenous chemotherapy in the treatment of hepatic metastases of colorectal origin: review of the literature and preliminary results].
Topics: Aged; Antineoplastic Agents; Colorectal Neoplasms; Female; Floxuridine; Fluorouracil; Hepatic Artery | 1990 |
Infusional versus systemic chemotherapy for liver metastases from colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Floxuridine; Hepatic Artery; Humans; Infus | 1989 |
[Current results and prospects of intra-arterial chemotherapy in hepatic metastases of carcinoma of the colorectum].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Flox | 1989 |
Cytostatic drug therapy in disseminated colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Col | 1988 |
[Therapy concepts in colorectal liver metastases. What is proven, what is open to discussion?].
Topics: Colorectal Neoplasms; Combined Modality Therapy; Floxuridine; Fluorouracil; Hepatectomy; Humans; Inf | 1988 |
Adjuvant cytotoxic chemotherapy for colorectal cancer: the present position.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combine | 1988 |
95 trials available for floxuridine and Colorectal Cancer
| Article | Year |
|---|---|
Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; | 2020 |
A Randomized Phase II Trial of Adjuvant Hepatic Arterial Infusion and Systemic Therapy With or Without Panitumumab After Hepatic Resection of KRAS Wild-type Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; C | 2021 |
Adjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases - the multicenter randomized controlled PUMP trial.
Topics: Adult; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; | 2019 |
UDP-glucuronosyltransferase (UGT) 1A1*28 polymorphism-directed phase II study of irinotecan with 5'-deoxy-5-fluorouridine (5'-DFUR) for metastatic colorectal cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2013 |
Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030).
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Capecitabine; Colorectal Neopl | 2013 |
Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherap | 2015 |
Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherap | 2015 |
Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherap | 2015 |
Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherap | 2015 |
[Hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: a phase II trial].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Flo | 2014 |
Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; China; Colorectal Neoplas | 2014 |
[A randomized controlled trial of postoperative adjuvant chemotherapy for colorectal cancer-optimal duration of the treatment].
Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Floxuridine; Follo | 2009 |
Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2009 |
Phase I study of irinotecan and doxifluridine for metastatic colorectal cancer focusing on the UGT1A1*28 polymorphism.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2010 |
Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) phase II intergroup trial, N9945/CI-
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cat | 2010 |
Plasma disposition of capecitabine and its metabolites 5'DFCR and 5'DFUR in a standard and dose-intensified monotherapy regimen.
Topics: Aged; Antimetabolites, Antineoplastic; Area Under Curve; Capecitabine; Colorectal Neoplasms; Cross-O | 2011 |
Hepatic arterial infusion with oxaliplatin, irinotecan and doxifluridine for unresectable liver metastases of colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therap | 2010 |
Hepatic arterial infusion and systemic chemotherapy after multiple metastasectomy in patients with colorectal carcinoma metastatic to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study, 92-46-52.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2012 |
Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot | 2011 |
Hepatic arterial infusion with irinotecan, oxaliplatin, and floxuridine plus systemic chemotherapy as first-line treatment of unresectable liver metastases from colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fl | 2012 |
Factors predicting the response to oral fluoropyrimidine drugs: a phase II trial on the individualization of postoperative adjuvant chemotherapy using oral fluorinated pyrimidines in stage III colorectal cancer treated by curative resection (ACT-01 Study)
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Colorectal | 2013 |
Systemic irinotecan or regional floxuridine chemotherapy prolongs survival after hepatic cryosurgery in patients with metastatic colon cancer refractory to 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Camptothecin; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regiona | 2001 |
Oral doxifluridine plus leucovorin in metastatic colorectal cancer: randomized phase II trial with intravenous 5-fluorouracil plus leucovorin.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Floxuridine; Fluorouraci | 2003 |
Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2003 |
A randomized controlled trial of postoperative adjuvant immunochemotherapy for colorectal cancer with oral medicines.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Colorect | 2003 |
Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2003 |
Gene expression profiles of colorectal carcinoma in response to neo-adjuvant chemotherapy.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pr | 2004 |
Sequential treatment with irinotecan and doxifluridine: optimal dosing schedule in murine models and in a phase I study for metastatic colorectal cancer.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neopl | 2005 |
Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, In | 2005 |
A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Comb | 2008 |
Pyrimidine nucleoside phosphorylase and dihydropyrimidine dihydrogenase activities as predictive factors for the efficacy of doxifluridine together with mitomycin C as adjuvant chemotherapy in primary colorectal cancer.
Topics: Adult; Aged; Antineoplastic Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Dihydrouracil D | 2007 |
A phase II study of irinotecan, high-dose 24-h continuous intravenous infusion of floxuridine and leucovorin (IFLUX) for advanced, previously untreated colorectal cancer.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineop | 2007 |
Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases.
Topics: Anxiety; Aspartate Aminotransferases; Bilirubin; Carcinoembryonic Antigen; Cause of Death; Colorecta | 1994 |
Treatment of hepatic-metastatic colorectal cancer with a chemotherapeutic emulsion: interim results of a phase I trial.
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Emulsions; Female; Floxuridine; Hepatic | 1995 |
Doxifluridine and leucovorin: an oral treatment combination in advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 1995 |
[Chrono-chemotherapy and dose intensity].
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chronobiology | 1995 |
The treatment of colorectal liver metastases with conformal radiation therapy and regional chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Combined Modality Therapy; Female; Floxuridine | 1995 |
Suramin in patients with metastatic colorectal cancer pretreated with fluoropyrimidine-based chemotherapy. A phase II study.
Topics: Adult; Aged; Colorectal Neoplasms; Female; Floxuridine; Fluorouracil; Humans; Male; Middle Aged; Neo | 1995 |
Oral doxifluridine in elderly patients with metastatic colorectal cancer: a multicenter phase II study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Diarrhea | 1994 |
[Hepatic arterial infusion after hepatectomy for liver metastases of colorectal carcinoma to prevent residual hepatic recurrence].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Floxuridine; Flu | 1994 |
[Adjuvant chemo-endocrine chemotherapy with gastrin antagonist after resection of liver metastasis in colorectal cancer].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 1994 |
[A study of preoperative administration of 5'-DFUR in patients with colo-rectal cancer].
Topics: Administration, Oral; Antineoplastic Agents; Colorectal Neoplasms; Floxuridine; Fluorouracil; Humans | 1994 |
Phase II study of hepatic arterial floxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Colorecta | 1994 |
[Study of 5'-DFUR treatment as postoperative adjuvant chemotherapy for stomach and colorectal cancer. Tokai GATS Group (pilot study)].
Topics: Administration, Oral; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diarrhea; | 1994 |
Fluorodeoxyuridine with continuous leucovorin infusion. A phase II clinical trial in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Colorectal Neoplasms; Diarrhea; Drug Therapy, Combination; Female; Floxuridine; Humans; | 1993 |
Hepatic arterial floxuridine and leucovorin for unresectable liver metastases from colorectal carcinoma. New dose schedules and survival update.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; Drug A | 1994 |
Prospective randomised trial comparing fluorouracil versus doxifluridine for the treatment of advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Female; Floxuridine; Fluorouracil; Humans; | 1993 |
Randomized trial of hepatic arterial floxuridine, mitomycin, and carmustine versus floxuridine alone in previously treated patients with liver metastases from colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colorect | 1993 |
A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cholangitis, Sclerosing; Colorectal Neoplasms; Dexam | 1993 |
A pilot study of hepatic artery floxuridine combined with systemic 5-fluorouracil and leucovorin. A potential adjuvant program after resection of colorectal hepatic metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 1993 |
Chronomodulated 5-day infusion of floxuridine and L-folinic acid in patients with advanced malignancies: a feasibility and tolerability study.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Chronobiology Phenom | 1995 |
[Quality of life and survival after continuous intrahepatic floxuridine infusions in liver metastases of colorectal carcinomas].
Topics: Chemotherapy, Adjuvant; Colorectal Neoplasms; Floxuridine; Follow-Up Studies; Humans; Infusions, Int | 1995 |
Effect of low dose cyclophosphamide on the synthesis of acute phase protein and its significance for cancer chemotherapy.
Topics: Acute-Phase Proteins; Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemothera | 1996 |
Randomized phase II noncomparative trial of oral and intravenous doxifluridine plus levo-leucovorin in untreated patients with advanced colorectal carcinoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antidotes; Antineoplastic Agents; Colorectal N | 1996 |
Effect of regional and systemic fluorinated pyrimidine chemotherapy on quality of life in colorectal liver metastasis patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hum | 1997 |
Doxifluridine in colorectal cancer patients resistant to 5-fluorouracil (5-FU) containing regimens.
Topics: Administration, Oral; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents | 1997 |
Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomar | 1997 |
Differential device performances for hepatic arterial chemotherapy: a technical report on totally implantable pumps and ports for both continuous and bolus infusion.
Topics: Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Female; Floxuridine; Humans; Infusion Pump | 1998 |
Sequential intrahepatic fluorodeoxyuridine and systemic fluorouracil plus leucovorin for the treatment of metastatic colorectal cancer confined to the liver.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv | 1998 |
Results of leucovorin and doxifluridine oral regimen in the treatment of metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 1998 |
Hepatic arterial floxuridine as second-line treatment for systemic fluorouracil-resistant colorectal liver metastases.
Topics: Colorectal Neoplasms; Drug Resistance, Neoplasm; Floxuridine; Fluorouracil; Hepatic Artery; Humans; | 1998 |
[Intra-arterial (5-FU/FA and FUDR) versus systemic chemotherapy (5-FU/FA) of non-resectable colorectal liver metastases].
Topics: Adult; Aged; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; F | 1998 |
Phase II evaluation of treatment of complete resection of hepatic metastases from colorectal cancer and adjuvant hepatic arterial infusion of floxuridine: an Eastern Cooperative Oncology Group Study (PB083).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; | 1999 |
Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Clocks; Colonic Neoplasms; C | 1999 |
[Antitumor effect of 5'-DFUR and PyNPase activity in colorectal cancer].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Agents; Colorectal Neoplasms; Drug Admini | 1999 |
Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; C | 1999 |
Selective augmentations of intratumoral 5-fluorouracil concentration by local immunotherapy with OK-432 and fibrinogen.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Chemotherapy, Adjuvant; Colon; Colorec | 2000 |
Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Colorect | 2000 |
Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Colorect | 2000 |
Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Colorect | 2000 |
Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Colorect | 2000 |
Randomized trial of regional plus systemic fluorinated pyrimidine compared with systemic fluorinated pyrimidine in treatment of colorectal liver metastases.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoembryonic Antigen; Colorectal Neopl | 2000 |
Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusio | 2001 |
[Preoperative chemotherapy for advanced colorectal carcinomas--comparison of histological effect between 5'-DFUR + leucovorin tablet and 5'-DFUR alone].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administrati | 2001 |
Variations in 5-fluorouracil concentrations of colorectal tissues as compared with dihydropyrimidine dehydrogenase (DPD) enzyme activities and DPD messenger RNA levels.
Topics: Antimetabolites, Antineoplastic; Colon; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Do | 2001 |
[Combination chemotherapy of doxifluridine plus mitomycin C for colorectal lung metastasis--phase II study].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2001 |
Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Di | 2001 |
Systemic irinotecan and regional floxuridine after hepatic cytoreduction in 185 patients with unresectable colorectal cancer metastases.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; California; Camptothecin; Colorectal | 2002 |
Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy--an intergroup study.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm | 2002 |
Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial.
Topics: Colorectal Neoplasms; Drug Administration Schedule; Female; Floxuridine; Hepatic Artery; Humans; Inf | 1992 |
A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dexamethasone; Do | 1992 |
Phase II study of pulse 5-fluoro-2'-deoxyuridine and leucovorin in advanced colorectal cancer patients previously treated with chemotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Adm | 1992 |
Continuous regional treatment with fluoropyrimidines for metastases from colorectal carcinomas: influence of modulation with leucovorin.
Topics: Colorectal Neoplasms; Drug Administration Schedule; Female; Floxuridine; Fluorouracil; Hepatic Arter | 1992 |
Is hepatic infusion of chemotherapy effective treatment for liver metastases? No!
Topics: Antineoplastic Agents; Colorectal Neoplasms; Floxuridine; Fluorouracil; Forecasting; Humans; Infusio | 1992 |
Alternating hepatic intra-arterial floxuridine and fluorouracil: a less toxic regimen for treatment of liver metastases from colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Evaluation; Female; Floxu | 1991 |
[Regional chemotherapy of liver metastases].
Topics: Antineoplastic Agents; Colorectal Neoplasms; Floxuridine; Humans; Infusions, Intra-Arterial; Liver N | 1991 |
Two consecutive clinical trials on cisplatin (CDDP), hepatic arterial infusion (HAI), and i.v. 5-fluorouracil (5-FU) chemotherapy for unresectable colorectal liver metastases: an alternative to FUdR-based regimens?
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Evaluation; Floxuridine; | 1991 |
Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial.
Topics: Adenocarcinoma; Aged; Colorectal Neoplasms; Female; Floxuridine; Fluorouracil; Humans; Infusion Pump | 1990 |
Cancer chronotherapy: a drug delivery challenge.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Circadian Rhythm; Colorectal Neoplasms; Drug | 1990 |
A prospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 1990 |
[Is there a primary indication for regional therapy of liver metastases of gastrointestinal tumors?].
Topics: Antineoplastic Agents; Clinical Trials as Topic; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hu | 1989 |
Regional chemotherapy for hepatic metastases of colorectal carcinoma (continuous intraarterial versus continuous intraarterial/intravenous therapy). Results of a controlled clinical trial.
Topics: Adenocarcinoma; Carcinoembryonic Antigen; Clinical Trials as Topic; Colorectal Neoplasms; Female; Fl | 1989 |
Value of in vivo tissue testing in predicting the clinical response to regional perfusion chemotherapy in colorectal cancer patients with liver metastases.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colorect | 1989 |
[Regional chemotherapy of liver metastases in colorectal carcinoma. Intra-arterial vs intravenous plus intra-arterial therapy].
Topics: Adult; Aged; Colorectal Neoplasms; Combined Modality Therapy; Evaluation Studies as Topic; Female; F | 1989 |
[Current results and prospects of intra-arterial chemotherapy in hepatic metastases of carcinoma of the colorectum].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Flox | 1989 |
A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial.
Topics: Adult; Aged; Colorectal Neoplasms; Drug Implants; Floxuridine; Hepatic Artery; Humans; Infusions, In | 1989 |
Prevention of extrahepatic disease during intraarterial floxuridine of colorectal liver metastases by simultaneous systemic 5-fluorouracil treatment? A prospective multicenter study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Inju | 1989 |
Effect of dipyridamole on fluorodeoxyuridine cytotoxicity in vitro and in cancer patients.
Topics: Bone Marrow; Cell Line; Chromatography, High Pressure Liquid; Clinical Trials as Topic; Colorectal N | 1989 |
[European topic: liver surgery II--regional chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Flo | 1989 |
Cytostatic drug therapy in disseminated colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Col | 1988 |
The pharmacokinetics of doxifluridine and 5-fluorouracil after single intravenous infusions of doxifluridine to patients with colorectal cancer.
Topics: Adult; Aged; Colorectal Neoplasms; Female; Floxuridine; Fluorouracil; Half-Life; Humans; Infusions, | 1988 |
140 other studies available for floxuridine and Colorectal Cancer
| Article | Year |
|---|---|
Hepatic arterial infusion pump chemotherapy combined with systemic therapy for patients with advanced colorectal liver metastases: Outcomes in a newly established program.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hep | 2022 |
Evaluation of biliary toxicity in patients with hepatic artery infusion pumps.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic | 2023 |
Systemic exposure of floxuridine after hepatic arterial infusion pump chemotherapy with floxuridine in patients with resected colorectal liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Floxuridine; Humans; Infusion | 2023 |
Starting a successful hepatic artery infusion pump program: A practical guide.
Topics: Colorectal Neoplasms; Floxuridine; Hepatic Artery; Humans; Infusion Pumps, Implantable; Infusions, I | 2023 |
Inhibition of Human Uracil DNA Glycosylase Sensitizes a Large Fraction of Colorectal Cancer Cells to 5-Fluorodeoxyuridine and Raltitrexed but Not Fluorouracil.
Topics: Antineoplastic Agents; Cell Line, Tumor; Colorectal Neoplasms; DNA Damage; Drug Screening Assays, An | 2021 |
Effectiveness of Hepatic Artery Infusion (HAI) Versus Selective Internal Radiation Therapy (Y90) for Pretreated Isolated Unresectable Colorectal Liver Metastases (IU-CRCLM).
Topics: Antimetabolites, Antineoplastic; Brachytherapy; Colorectal Neoplasms; Combined Modality Therapy; Emb | 2018 |
Selective depletion of metastatic stem cells as therapy for human colorectal cancer.
Topics: Animals; Antineoplastic Agents; Colorectal Neoplasms; Disease Models, Animal; Drug Therapy; Floxurid | 2018 |
Transarterial chemoembolization with raltitrexed-based or floxuridine-based chemotherapy for unresectable colorectal cancer liver metastasis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; Colorectal Neo | 2019 |
Implementation and early outcomes for a surgeon-directed hepatic arterial infusion pump program for colorectal liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Body Fat Distribution; Colorectal N | 2018 |
Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, and 5-fluorouracil.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under Cu | 2019 |
Floxuridine hepatic arterial infusion associated biliary toxicity is increased by concurrent administration of systemic bevacizumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bile | 2014 |
Debulking treatment with CT-guided percutaneous radiofrequency ablation and hepatic artery infusion of floxuridine improves survival of patients with unresectable pulmonary and hepatic metastases of colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Colorectal Neoplasms; Combi | 2014 |
Impact of co-administered drugs on drug monitoring of capecitabine in patients with advanced colorectal cancer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2014 |
Clinical pharmacokinetics of capecitabine and its metabolites in combination with the monoclonal antibody bevacizumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cape | 2014 |
[Transfection of thymidine phosphorylase cDNA with lentiviral vector enhances the anticancer effect of 5'-deoxy-5-fluorouridine on colorectal cancer cell lines HT29 and LS174T].
Topics: Antineoplastic Agents; Cell Line; Cell Line, Tumor; Colorectal Neoplasms; DNA, Complementary; Floxur | 2015 |
Synergistic Combination Chemotherapy of Camptothecin and Floxuridine through Self-Assembly of Amphiphilic Drug-Drug Conjugate.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Proliferation; Colon; Colorec | 2015 |
First-line treatment with hepatic arterial infusion plus capecitabine vs capecitabine alone for elderly patients with unresectable colorectal liver metastases.
Topics: Aged; Aged, 80 and over; Capecitabine; Colorectal Neoplasms; Female; Floxuridine; Hepatic Artery; Hu | 2016 |
Updated long-term survival for patients with metastatic colorectal cancer treated with liver resection followed by hepatic arterial infusion and systemic chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Ch | 2016 |
Hepatic Arterial Infusion in Combination with Modern Systemic Chemotherapy is Associated with Improved Survival Compared with Modern Systemic Chemotherapy Alone in Patients with Isolated Unresectable Colorectal Liver Metastases: A Case-Control Study.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Case-Con | 2017 |
Response rates of hepatic arterial infusion pump therapy in patients with metastatic colorectal cancer liver metastases refractory to all standard chemotherapies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemother | 2016 |
Hepatic arterial infusion chemotherapy for metastases from colorectal cancer: is it really the end of an era?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Colorectal Neoplasms; Floxuridine; Fluoroura | 2008 |
Immunochemotherapy with PSK and fluoropyrimidines improves long-term prognosis for curatively resected colorectal cancer.
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined M | 2008 |
Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma.
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Dexamethasone; | 2009 |
Hepatic arterial infusion for unresectable colorectal liver metastases combined or not with systemic chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colorectal Neoplasms; D | 2009 |
In defense of hepatic arterial infusion for hepatic metastases of colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 2010 |
The relationship between clinicopathological factors and the reduction of pyrimidine nucleoside phosphorylase activity after preoperative administration of 5'-deoxy-5-fluorouridine.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Floxuridine; Humans; Pentosyltransferases; Py | 2010 |
Clinical significance of microsatellite instability for stage II or III colorectal cancer following adjuvant therapy with doxifluridine.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Cohort Studies; Colorectal Neoplasms; Female | 2011 |
Selective intra-arterial chemotherapy with floxuridine as second- or third-line approach in patients with unresectable colorectal liver metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colorectal Neoplasms; F | 2011 |
Significance of microsatellite instability (MSI) for colorectal cancer following adjuvant therapy with doxifluridine.
Topics: Colorectal Neoplasms; Female; Floxuridine; Humans; Male; Microsatellite Instability | 2012 |
Biliary sclerosis after hepatic arterial infusion pump chemotherapy for patients with colorectal cancer liver metastasis: incidence, clinical features, and risk factors.
Topics: Adult; Aged; Aged, 80 and over; Biliary Tract Diseases; Causality; Cohort Studies; Colorectal Neopla | 2012 |
Reliability of tumor primary cultures as a model for drug response prediction: expression profiles comparison of tissues versus primary cultures from colorectal cancer patients.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; | 2012 |
A thymidylate synthase ternary complex-specific antibody, FTS, permits functional monitoring of fluoropyrimidines dosing.
Topics: Animals; Antibodies, Monoclonal; Antibody Specificity; Colorectal Neoplasms; Dose-Response Relations | 2012 |
Floxuridine coupling with lactosaminated human albumin to increase drug efficacy on liver micrometastases.
Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Carriers; Drug Delivery Systems | 2002 |
Laparoscopic radiofrequency ablation and hepatic artery infusion pump placement in the evolving treatment of colorectal hepatic metastases.
Topics: Adult; Aged; Aged, 80 and over; Catheter Ablation; Chemotherapy, Adjuvant; Colorectal Neoplasms; Dis | 2003 |
Technical complications of continuous intra-arterial chemotherapy with 5-fluorodeoxyuridine and 5-fluorouracil for colorectal liver metastases.
Topics: Antimetabolites, Antineoplastic; Catheterization; Colorectal Neoplasms; Disease-Free Survival; Femal | 2003 |
Hepatic artery infusion for liver metastases from colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothe | 2003 |
[Optimal dosing schedule in combination therapy with irinotecan and doxifluridine in a human colorectal cancer xenograft model].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorecta | 2003 |
Hepatic artery chemotherapy and colorectal liver metastases.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Controlled Clinical Trials as Topic; Floxuridine; Fluor | 2003 |
Hepatic artery chemotherapy and colorectal liver mestastases.
Topics: Antineoplastic Agents; Catheters, Indwelling; Colorectal Neoplasms; Controlled Clinical Trials as To | 2003 |
Adjuvant hepatic arterial chemotherapy following metastasectomy in patients with isolated liver metastases.
Topics: Adult; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free S | 2003 |
Multidetector CT arteriography with volumetric three-dimensional rendering to evaluate patients with metastatic colorectal disease for placement of a floxuridine infusion pump.
Topics: Aged; Angiography, Digital Subtraction; Antimetabolites, Antineoplastic; Carcinoma; Colorectal Neopl | 2003 |
Can colorectal cancer patients with thymidylate synthase-overexpressing liver metastases have an overall survival advantage with hepatic arterial infusion alone?
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease Progression; Floxuridine; Fluorouraci | 2003 |
Pharmacokinetics of 5-fluorouracil following hepatic intra-arterial infusion in a VX2 hepatic metastasis model.
Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease Models, Animal; Drug Adminis | 2003 |
In vivo monitoring of capecitabine metabolism in human liver by 19fluorine magnetic resonance spectroscopy at 1.5 and 3 Tesla field strength.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fl | 2003 |
Correlation of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase with sensitivity of gastrointestinal cancer cells to 5-fluorouracil and 5-fluoro-2'-deoxyuridine.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; Dihydrouracil Dehydrogenase | 2004 |
Thymidylate synthetase mRNA levels are increased in liver metastases of colorectal cancer patients resistant to fluoropyrimidine-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Resistance, Neoplasm; Femal | 2004 |
[Thymidine phosphorylase expressed in monocyte-macrophages enhanced anticancer effect of 5'-deoxy-5-fluorouridine on colorectal carcinoma cells].
Topics: Adenocarcinoma; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineopla | 2004 |
Prediction of 5'-deoxy-5-fluorouridine sensitivity in colorectal cancer cases by thymidine phosphorylase activity and preliminary identification of susceptibility related genes.
Topics: Aged; Antimetabolites, Antineoplastic; Cell Division; Cell Line, Tumor; Colonic Neoplasms; Colorecta | 2004 |
In vitro and in vivo antitumor activity of novel amphiphilic dimers consisting of 5-fluorodeoxyuridine and arabinofuranosylcytosine.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Cytarabine; Drug | 2004 |
Hepatic artery infusion chemotherapy for metastatic colorectal cancer to the liver at the lahey clinic: comparison between two methods of treatment, surgical versus percutaneous catheter placement.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Brachial Artery; Catheterization, Peripheral; Colorect | 2004 |
Thymidine phosphorylase expression and efficacy of adjuvant doxifluridine in advanced colorectal cancer patients.
Topics: Administration, Oral; Aged; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Cell Differenti | 2005 |
Is there a new drug beyond floxuridine for intra-arterial hepatic chemotherapy in liver metastases from colorectal cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dexamethasone; F | 2005 |
A role for hepatic-directed chemotherapy in colorectal liver metastases.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as | 2005 |
Bile duct complications of hepatic arterial infusion chemotherapy evaluated by helical CT.
Topics: Adenocarcinoma; Adult; Aged; Alkaline Phosphatase; Antineoplastic Agents; Bile Duct Diseases; Biliru | 2005 |
[Long-term survival in a case of large bowel cancer--efficacy of CPT-11-based chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Color | 2005 |
The MMP-9 expression determined the efficacy of postoperative adjuvant chemotherapy using oral fluoropyrimidines in stage II or III colorectal cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemo | 2006 |
Simultaneous determination of capecitabine and its metabolites by HPLC and mass spectrometry for preclinical and clinical studies.
Topics: Animals; Capecitabine; Chromatography, High Pressure Liquid; Colorectal Neoplasms; Deoxycytidine; Dr | 2005 |
Perfusion chemotherapy for colorectal liver metastases: a randomized study comparing FUDR against 5-FU/BCNU.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colorectal Neoplasms; Floxuridine; Fluor | 1989 |
Radiation sensitiser effective against liver disease.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Floxuridine; Hepatic Artery; Humans; Infusion | 2006 |
Hepatic arterial infusion of chemotherapy for hepatic metastases from colorectal cancer.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Floxuridine; Hepatic Artery; Hu | 2006 |
Downstaging colorectal liver metastases by concomitant unilateral portal vein ligation and selective intra-arterial chemotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasm | 2006 |
The expression of vascular endothelial growth factor determines the efficacy of post-operative adjuvant chemotherapy using oral fluoropyrimidines in stage II or III colorectal cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemo | 2006 |
Genomic copy number changes affecting the thymidylate synthase (TYMS) gene in cancer: a model for patient classification to aid fluoropyrimidine therapy.
Topics: 5' Untranslated Regions; Alleles; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neop | 2006 |
[A treatment for pulmonary metastases from colorectal cancer by pre-operative CPT-11/5'-DFUR combination therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; | 2006 |
Saphenous vein graft conduits for insertion of hepatic arterial infusion pumps in patients with abnormal hepatic arterial anatomy.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Floxuridine; | 2008 |
Results of preoperative hepatic arterial infusion chemotherapy in patients undergoing liver resection for colorectal liver metastases.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Feasibility Studies; | 2008 |
Assessing the optimal duration of chemotherapy in patients with colorectal liver metastases.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Co | 2008 |
Treatment interruptions and complications with two continuous hepatic artery floxuridine infusion systems in colorectal liver metastases.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Floxuridine; Hepatic Artery; Humans; Infusion | 1995 |
Effect of aberrant hepatic arterial anatomy on tumour response to hepatic artery infusion of floxuridine for colorectal liver metastases.
Topics: Colorectal Neoplasms; Floxuridine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasm | 1995 |
[The therapy of the liver metastases of colorectal carcinoma].
Topics: Carcinoma; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Combined Modality Therapy | 1994 |
Isolated lung perfusion with FUDR is an effective treatment for colorectal adenocarcinoma lung metastases in rats.
Topics: Adenocarcinoma; Animals; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Female; Flo | 1995 |
Flow cytometric analysis of cell-killing actions of 5-fluorouracil in human colorectal cancer cells.
Topics: Cell Cycle; Cell Survival; Colorectal Neoplasms; DNA, Neoplasm; DNA, Ribosomal; Dose-Response Relati | 1994 |
Short-term intrahepatic FUdR infusion combined with bolus mitomycin C: reduced risk for developing drug resistance.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration S | 1994 |
Regional chemotherapy for colorectal liver metastases: thirty years without patient benefit.
Topics: Colorectal Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Incidence; Infusions, Intra | 1994 |
[The evolution of the liver metastases from colorectal carcinoma treated with hepatic intra-arterial chemotherapy. The echographic and CT aspects].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; Floxuridine; Fluoro | 1994 |
Genetic variation in thymidylate synthase confers resistance to 5-fluorodeoxyuridine.
Topics: Colorectal Neoplasms; Drug Resistance; Floxuridine; Genetic Variation; Humans; Ligands; Thymidylate | 1993 |
Resistance to fluorodeoxyuridine-induced DNA damage and cytotoxicity correlates with an elevation of deoxyuridine triphosphatase activity and failure to accumulate deoxyuridine triphosphate.
Topics: Cell Survival; Colorectal Neoplasms; Deoxyuracil Nucleotides; DNA Damage; DNA, Neoplasm; Drug Resist | 1993 |
[Study on the relationship between concentrations of 5-FU and PyNPase activity in tumor tissue during oral 5'-DFUR treatment in patients with advanced colorectal cancer].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Fema | 1994 |
[Adjuvant regional chemotherapy after resection of liver metastases of primary colorectal tumors].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 1993 |
Regional chemotherapy devices: effect of experience and anatomy on complications.
Topics: Adult; Analysis of Variance; Carcinoma, Hepatocellular; Catheters, Indwelling; Colorectal Neoplasms; | 1993 |
Regional hepatic arterial chemotherapy for colorectal cancer metastatic to the liver: the controversy continues.
Topics: Colorectal Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusion Pumps; Infusions, | 1993 |
Variation in human thymidylate synthase is associated with resistance to 5-fluoro-2'-deoxyuridine.
Topics: Binding Sites; Cell Division; Colorectal Neoplasms; Drug Resistance; Floxuridine; Humans; Thymidylat | 1993 |
Role of fluoropyrimidine Schedule and (6R,S)leucovorin dose in a preclinical animal model of colorectal carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Schedule; Female | 1996 |
Re: Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Hu | 1996 |
Regional chemotherapy for colorectal hepatic metastases: evidence for improved survival with new drug combinations.
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemo | 1996 |
Isolated lung perfusion with FUDR in the rat: pharmacokinetics and survival.
Topics: Animals; Antimetabolites, Antineoplastic; Chemotherapy, Cancer, Regional Perfusion; Chromatography, | 1996 |
Alternating floxuridine and 5-fluorouracil hepatic arterial chemotherapy for colorectal liver metastases minimizes biliary toxicity.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliar | 1996 |
[PyNPase activity in primary and metastatic colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Female; Floxuridine; Humans; L | 1997 |
[The relation between pyrimidine nucleoside phosphorylase (PyNPase) activity in colorectal cancer tissues and pathological effects].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; F | 1997 |
[Pyrimidine nucleoside phosphorylase activity, 5-fluorouracil concentration and thymidylate synthase inhibition rate in colorectal cancer after oral administration of 5'-doxifluridine].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Agents; Colorectal Neoplasms; Female; Flo | 1997 |
Management of symptomatic locoregional recurrence during regional chemotherapy for colorectal liver metastases.
Topics: Abdominal Neoplasms; Antimetabolites, Antineoplastic; Chemotherapy, Cancer, Regional Perfusion; Colo | 1998 |
Mechanisms for 5-fluorouracil resistance in human colon cancer DLD-1 cells.
Topics: Antimetabolites, Antineoplastic; Cell Count; Colorectal Neoplasms; Drug Resistance, Neoplasm; Floxur | 1998 |
[Adjuvant intra-arterial chemotherapy with gastrin receptor antagonist after hepatic resection in colorectal cancer metastasis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Doxoru | 1998 |
[Three cases of colorectal cancer with lung metastasis successfully treated with combination chemotherapy using 5'-DFUR and MMC].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Sch | 1998 |
[Comparative study of 5'-DFUR administration of single time per day versus two or three times].
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Drug Administration Sche | 1998 |
Colorectal liver metastasis thymidylate synthase staining correlates with response to hepatic arterial floxuridine.
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Floxuridine; Hepatic Artery; Hu | 1999 |
Increased cytotoxicity and bystander effect of 5-fluorouracil and 5-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Survival; Cloning, Molecular; Colorectal Neoplasms; DNA, | 1999 |
Overall survival or other clinical benefits from adjuvant selective intraarterial chemotherapy in patients undergoing curative liver resection for metastatic colorectal tumor.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Floxuridine; Humans; | 1999 |
Theoretical considerations and in vitro concentration response studies with two human colorectal carcinoma cell lines. The rational experimental base for clinical studies in regional chemotherapy.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2000 |
Hepatic arterial infusion of chemotherapy for metastatic colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Floxuridine; H | 2000 |
Hepatic arterial infusion of chemotherapy for metastatic colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dexamethasone; | 2000 |
Hepatic arterial infusion of chemotherapy for metastatic colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Data Interpret | 2000 |
Intra-abdominal fibrosis after systemic and intraperitoneal therapy containing fluoropyrimidines.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; | 2000 |
Different mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cells.
Topics: Antimetabolites, Antineoplastic; Cell Division; Colorectal Neoplasms; Drug Resistance, Neoplasm; Dru | 2000 |
Surrogate endpoints for new colorectal cancer drugs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hum | 2000 |
A joint analysis of quality of life and survival using a random effect selection model.
Topics: Algorithms; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Floxuridine; Humans; Infusion Pum | 2000 |
Sequential intrahepatic and systemic fluoropyrimidine-based chemotherapy for metastatic colorectal cancer confined to the liver. A phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv | 2001 |
[Effect of peroral doxifluridine plus hepatic arterial infusion for synchronous liver metastasis of colorectal cancer--correlation with the expression of thymidine phosphorylase and dihydropyrimidine dehydrogenase in primary colorectal cancer lesions].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dihydrouracil Dehydrogen | 2001 |
P53 mutation and response to hepatic arterial floxuridine in patients with colorectal liver metastases.
Topics: Adult; Antimetabolites, Antineoplastic; Binding Sites; Codon; Colorectal Neoplasms; DNA Mutational A | 2001 |
Fighting wars, winning battles.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; | 2002 |
Echogenicity of liver metastases from colorectal carcinoma is an independent prognostic factor in patients treated with regional chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma; Colorectal Neoplasms; Female; Flox | 2002 |
Downstaging of hepatocellular carcinoma and liver metastases from colorectal cancer by selective intra-arterial chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2002 |
In vitro enhancement of fluoropyrimidine-induced cytotoxicity by leucovorin in colorectal and gastric carcinoma cell lines but not in non-small-cell lung carcinoma cell lines.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Cell Survival; Colony-Forming Units Assay; Colorecta | 1992 |
Adjuvant chemotherapy for colorectal hepatic metastases: role of route of administration and timing.
Topics: Animals; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Floxuridine | 1992 |
Hepatic arterial floxuridine infusion and patient survival.
Topics: Colorectal Neoplasms; Floxuridine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasm | 1992 |
[The value of tumor volumetry as opposed to bidimensional determination of tumor size during follow-up of hepatic metastases from colorectal carcinoma].
Topics: Aged; Colorectal Neoplasms; Female; Floxuridine; Follow-Up Studies; Germany; Humans; Infusion Pumps, | 1992 |
Reversal of resistance to doxifluridine and fluorouracil in metastatic colorectal cancer: the role of high-dose folinic acid.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Resistance; | 1992 |
Interactions of interferon-alpha 2a with 5'-deoxy-5-fluorouridine in colorectal cancer cells in vitro.
Topics: Antineoplastic Agents; Cell Division; Colorectal Neoplasms; Dose-Response Relationship, Drug; Floxur | 1992 |
[Clinical use of a totally implantable and programmable pump for the infusion of drugs].
Topics: Antineoplastic Agents; Colorectal Neoplasms; Floxuridine; Humans; Infusion Pumps, Implantable; Kidne | 1992 |
[Continuous sinusoid systemic Fudr infusion in advanced colorectal carcinoma. Preliminary experience].
Topics: Circadian Rhythm; Colorectal Neoplasms; Drug Administration Schedule; Floxuridine; Humans; Infusions | 1992 |
Induction of megabase DNA fragments by 5-fluorodeoxyuridine in human colorectal tumor (HT29) cells.
Topics: Cell Survival; Colorectal Neoplasms; DNA; DNA Damage; Floxuridine; Gamma Rays; Humans; In Vitro Tech | 1991 |
Divergent patterns of incorporation of bromodeoxyuridine and iododeoxyuridine in human colorectal tumor cell lines.
Topics: Bromodeoxyuridine; Cell Division; Colorectal Neoplasms; DNA, Neoplasm; Floxuridine; Fluorouracil; Ga | 1991 |
Colorectal metastases to the liver: present results and future strategies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Fem | 1991 |
[Regional chemotherapy of diffuse liver metastases of colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 1991 |
[A study on preoperative administration of doxifluridine in carcinoma of the colon and rectum].
Topics: Adenocarcinoma; Administration, Oral; Colorectal Neoplasms; Floxuridine; Fluorouracil; Humans; Lymph | 1990 |
Continuous intrahepatic infusion of floxuridine and leucovorin through an implantable pump for the treatment of hepatic metastases from colorectal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colorectal Neoplasms; Flox | 1990 |
Regional chemotherapy in liver metastases of colorectal carcinoma: monitoring with arterial computed tomography.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Doxorub | 1990 |
Hepatic artery infusion chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Floxuridine; Hepatic Ar | 1990 |
Prognostic variables in patients with hepatic metastases from colorectal cancer. Importance of medical assessment of liver involvement.
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Aspartate Aminotransferases; Bilirubin; Colorecta | 1989 |
[Computed tomographic and angiographic studies of arterial liver perfusion following intra-arterial infusion chemotherapy using 5-fluoro-2-deoxyuridine].
Topics: Aged; Angiography; Arterial Occlusive Diseases; Colorectal Neoplasms; Female; Floxuridine; Humans; I | 1989 |
Intra-arterial hepatic chemotherapy for metastatic liver from colo-rectal carcinoma origin.
Topics: Adenocarcinoma; Adult; Aged; Colorectal Neoplasms; Female; Floxuridine; Fluorouracil; Hepatic Artery | 1989 |
Intrahepatic mitomycin C as a salvage treatment for patients with hepatic metastases from colorectal carcinoma.
Topics: Colorectal Neoplasms; Female; Floxuridine; Humans; Leukocyte Count; Liver Neoplasms; Male; Mitomycin | 1989 |
Regional chemotherapy for hepatic metastases from colorectal carcinoma.
Topics: Colorectal Neoplasms; Floxuridine; Fluorouracil; Humans; Infusions, Intra-Arterial; Liver Neoplasms | 1989 |
Treatment of liver metastases from colorectal cancer with continuous high dose intra-arterial floxuridine (FUDR) and systemic fluorouracil: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Evaluation; | 1989 |
Hepatic perfusion with FUdR utilizing an implantable system in patients with liver primary cancer or metastatic cancer confined to the liver.
Topics: Adenocarcinoma; Adenoma, Bile Duct; Adult; Aged; Carcinoma, Hepatocellular; Colorectal Neoplasms; Fl | 1989 |
[Biliary and arterial obstructive processes in regional chemotherapy with FUDR].
Topics: Adult; Aged; Arterial Occlusive Diseases; Cholestasis, Intrahepatic; Colorectal Neoplasms; Female; F | 1988 |
Enhancement of fluorinated pyrimidine-induced cytotoxicity by leucovorin in human colorectal carcinoma cell lines.
Topics: Carcinoma; Cell Survival; Colorectal Neoplasms; Drug Synergism; Floxuridine; Fluorouracil; Humans; L | 1988 |
[Rationale and current results of loco-regional chemotherapy in hepatic metastases of colorectal carcinoma].
Topics: Antineoplastic Agents; Carmustine; Cisplatin; Colorectal Neoplasms; Doxorubicin; Floxuridine; Fluoro | 1987 |
The antiproliferative effects of fluoropyrimidine derivatives against human tumor xenografts in a subrenal capsule assay.
Topics: Animals; Antineoplastic Agents; Body Weight; Cell Division; Colorectal Neoplasms; Floxuridine; Fluor | 1988 |
The role of thymidylate synthase in the response to fluoropyrimidine-folinic acid combinations.
Topics: Cell Line; Clone Cells; Colorectal Neoplasms; Drug Resistance; Floxuridine; Humans; Leucovorin; Thym | 1988 |